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ABSTRACT 
 Vaccinia virus (VACV) is the current vaccine for the highly infectious smallpox 
disease. Since the eradication of smallpox, VACV has been developed extensively as a 
heterologous vaccine vector for several pathogens. However, due to the complications 
associated with this replication competent virus, the safety and efficacy of VACV 
vaccine vector has been reevaluated. To evaluate the safety and efficacy of VACV, we 
study the interactions between VACV and the host innate immune system, especially the 
type I interferon (IFN) signaling pathways. In this work, we evaluated the role of protein 
kinase R (PKR) and Adenosine Deaminase Acting on RNA 1(ADAR1), which are 
induced by IFN, in VACV infection. We found that PKR is necessary but is not sufficient 
to activate interferon regulatory factor 3 (IRF3) in the induction of type I IFN; and the 
activation of the stress-activated protein kinase/ c-Jun NH2-terminal kinase is required for 
the PKR-dependent activation of IRF3 during VACV infection. Even though PKR was 
found to have an antiviral effect in VACV, ADAR1 was found to have a pro-viral effect 
by destabilizing double stranded RNA (dsRNA), rescuing VACVΔE3L, VACV deleted 
of the virulence factor E3L, when provided in trans. With the lessons we learned from 
VACV and host cells interaction, we have developed and evaluated a safe replication-
competent VACV vaccine vector for HIV. Our preliminary results indicate that our 
VACV vaccine vector can still induce the IFN pathway while maintaining the ability to 
replicate and to express the HIV antigen efficiently. This suggests that this VACV vector 
can be used as a safe and efficient vaccine vector for HIV.  
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OVERALL INTRODUCTION 
 Infectious diseases are caused by pathogens such as bacteria, viruses, parasites or 
fungi. Fortunately, many diseases can be prevented through vaccination, one of the most 
effective public health interventions. Vaccination was first introduced by Edward Jenner 
in the 1700s (164), and was the foundation of the eradication of smallpox, a highly 
dangerous and contagious pathogen, in the 1970s. In our lab, we study and develop 
vaccinia virus (VACV) as a vaccine vector for several infectious pathogens such as the 
Human Immunodeficiency Virus (HIV), and the African Swine Virus (ASV). In order to 
develop a safe and efficient VACV vaccine vector, we study the interactions between 
VACV proteins and host cellular proteins. These studies give us the insight into 
genetically engineering VACV as a safe and efficient vaccine vector. 
Viruses are obligate intracellular pathogens that require the host cellular 
machinery for their survival. In contrast the host cells have developed several 
mechanisms to prevent viruses from establishing successful infection. One of these 
mechanisms is the interferon (IFN) system of the innate immune system. IFNs were the 
first cytokine discovered to have the ability to interfere with virus survival (80). The IFN 
system is classified into three types (24) in which type I IFNs (IFN-α/β) are the most well 
studied and are known primarily to inhibit viral replication (9). The innate immune 
system relies primarily on type I IFNs as its first line of defense against viral infection 
(171, 176). 
The IFN signal transduction pathway consists of two signaling cascades: a virus-
induced IFN production signal and an IFN receptor-mediated secondary signal to 
establish an antiviral state (78, 206). The virus-induced IFN production signal is initiated 
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by the detection of pathogen-associated molecular patterns (PAMPs) by host pattern 
recognition receptors (PRRs). PAMPs are components or byproducts of microorganisms 
during theirs life cycle inside the host. The most common PAMP in viral infection is viral 
nucleic acids, including viral genomic deoxy-ribose nucleic acid (DNA), single stranded 
ribose nucleic acid (ssRNA), and double stranded RNA (dsRNA) (2). These PAMPs can 
be recognized by four classes of pathogen recognition proteins (PRPs): toll-like receptors 
(TLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs), and cytoplasmic DNA sensors 
(89). TLRs and RLRs have been shown to be important in regulating the induction of 
type I IFNs (221), which is a critical cytokine of the antiviral response, while NLRs have 
been shown to regulate the production of interleukin-1 (IL-1) (86, 153). 
 TLRs are found on the cell surface or within the lumen of endosomes or 
lysosomes. TLRs are type I transmembrane proteins in which the N-terminal is outside of 
the membrane. They consist of an extracellular ligand recognition domain, a single 
transmembrane helix, and a C-terminal cytoplasmic signaling domain, known as the Toll-
interleukin 1 receptor homology domain (TIR) (21). Currently, there are 10 members of 
mammalian TLR (1) in which TLR3, TLR7, TLR8 and TLR9 have been shown to 
recognize only viral nucleic acids (27), thus suggesting its role in prevention of viral 
infection. These TLRs are found within the lumen of endosome, lysosome and ER (101, 
139). TLR3 can recognize various form of dsRNA such as synthetic polyinosinic-
polycytidylic acid (poly IC), genomic dsRNA such as reovirus (RSV) (7, 118), or 
byproduct dsRNA made during the course of  VACV, encephalomyocarditis virus 
(EMCV) infection and West Nile virus (WSV) infection (7, 45, 208). TLR7 and TLR8 
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are phylogenetically similar, both recognize ssRNA and are mostly activated during the 
course of RNA virus’s infections (52, 74). In contrast, TLR9 recognizes unmethylated 2′-
deoxyribo cytidine–phosphate–guanosine (CpG) DNA motifs presenting in several DNA 
viruses such as Herpes simplex virus 1 and 2 (HSV1/HSV2) (94, 113) and mouse 
cytomegalovirus (MCMV) (94). All known TLRs, with the exception of TLR3, signal 
through the adaptor protein myeloid differentiation primary response gene 88 (MyD88) 
leading to the activation of nuclear factor kappa B (NF-κB), interferon regulatory factor 7 
(IRF7) and mitogen-activated protein kinases (MAPKs), which induce inflammatory 
cytokines (1, 83). TLR3 signals through the adaptor protein TIR-domain-containing 
adapter-inducing interferon-β (TRIF) (220) lead to the activation of NF-κB, MAPKs, and 
especially interferon regulatory factor 3 (IRF3) to induce expression of IFN-β (90). With 
the inductions of IFN-β and various inflammatory cytokines, the infected cells can induce 
an antiviral state against the incoming viral infection. 
 RLRs are cytoplasmic proteins that can detect viral RNA (221) in various cell 
types (87). Three members of this family have been identified: RIG-I (223), melanoma 
differentiation-associated gene 5 (MDA5) (85) and laboratory of genetics and physiology 
2 (LGP2) (167). These RLRs consist of two tandem N-terminal caspase-recruitment 
domains (CARDs), a DExD/H box RNA helicase domain, and a well conserved C-
terminal repressor domain; in contrast, LGP2 only consist of one CARD domain (196).  
LGP2 has been suggested to be a negative regulator of the RLRs signaling (167, 222). 
Although both RIG-I and MDA-5 are interferon inducible proteins, RIG-I detects short 
dsRNA and 5’-triphosphate ssRNA while MDA5 detects long dsRNA. Upon detection of 
viral RNA, the CARDs of RIG-I/MDA5 associate with the CARD of the mitochondrial 
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adapter protein IFN-β promoter stimulator-1 (IPS-1) (155), which is also known as 
mitochondrial antiviral signaling (MAVS), virus-induced signaling adapter (VISA), or 
CARD adapter inducing IFN-β (CARDIF) (91, 128, 178). In turn, activated IPS-1 
associates with tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3) (169) 
which recruits and activates TANK-binding kinase (TBK-1), and inhibitor of NF-κB 
kinase ε (IKKε) (75, 179). Activated IKKε subsequently phosphorylates IRF3 (60) 
leading to the formation of IRF3 homodimer, which translocates into the nucleus (157) 
and bind to positive regulatory domain (PRD) regions of the IFN promoter, resulting in 
the expression of type I IFNs. 
 Once the expressed IFN-α/β is secreted outside of the infected cells, it can bind to 
the IFN-α/β receptor (IFN-α/βR) of the same cell for an autocrine effect or they can bind 
to the IFRNs of an adjacent cell for a paracrine effect. The IFN-α/βR composes of two 
subunits: IFNAR-1 and IFNAR-2 (140, 190, 205). Biding of IFNs to its receptor activates 
the downstream Janus kinase (JAK) pathway (190). These kinases in turn phosphorylate 
their downstream substrates which are the signal transducer and activator of transcription 
(STAT) (105, 190). This leads to the formation of IFN-stimulated gene factor 3 (ISGF3) 
(23, 48), which consists of STAT1, STAT2 and IRF9. This complex translocates into the 
nucleus, binds to the IFN-stimulated response element (ISRE)  and induces the 
transcriptions of several IFN-stimulated genes (ISGs) (50, 190). Most of ISGs serves as 
antiviral component during the course of viral infection. 
 Protein kinase R (PKR) is among those ISGs that have antiviral effects. It is 
expressed constitutively and ubiquitously in most cells and is highly expressed upon IFN 
induction (168). It is composed of two N-terminal dsRNA binding motifs (dsRNA-BM) 
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and a C-terminal serine/threonine kinase domain (127). Activation of PKR is through 
binding to dsRNA, followed by homodimerization and autophosphorylation in the kinase 
domain (41). In turn, activated PKR phosphorylates its target, the α subunit of eukaryotic 
initiation factor 2 (eIF2α), at serine 51 leading to the inhibition of global protein synthesis 
(112, 142). Thus, PKR can inhibit virus survival by inhibiting viral protein synthesis. It 
has been suggested that IRF3 can be activated in a PKR-dependent manner (228). 
Chapter 1 of this dissertation will confirm this finding in the vaccinia virus system. 
 PKR has also been reported to be involved in MAPK signaling, especially p38 
and stress-activated protein kinase/c-Jun N-terminal kinases (SAPK/JNK) (8, 69, 79, 
195). P38 and SAPK/JNK are among the stress-associated kinases that are activated by 
UV radiation, detection of bacteria liposaccharides (LPS), or dsRNA during viral 
infection (11, 217). They are also key components of the innate immune system, 
especially the interferon pathway, due to their roles in activation of AP-1 family 
transcription factors c-Jun and ATF-2, which lead to the induction of several pro-
inflammatory cytokine genes (88, 110). Since there was evidence linking PKR, p38, 
SAPK/JNK to the activation of IRF3 (226, 228), we asked if these kinases are required 
for the activation of IRF3. This work is described in chapter 1. 
 Another important antiviral ISGs is the 2’-5’-oligoadenylate synthetase 
(OAS)/RNase L, which can also be activated by dsRNA (162, 185). Upon binding to 
dsRNA, OAS uses Adenosine Triphosphate (ATP) to synthesize 2’-5’adenylate 
molecules, called 2-5A, that subsequently activate the latent endonuclease RNase L 
resulting in the degradation of viral messenger RNA (mRNA) and cellular mRNA and 
ribosomal RNA (rRNA) (61, 218) thus leading to an arrest of protein synthesis (216). 
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RNase L has been reported to have antiviral effects in several viruses (184). RNase L can 
also induce the production of IFNs by activation of RIG-I/MDA5 to furthermore induce 
the antiviral state during viral infection (115). By working in synergy, PKR and OAS 
ensure the inhibition of viral protein synthesis. 
 Although the main function of ISGs is to establish the antiviral state, there are 
ISGs that can be either antiviral or proviral, dependent upon virus and host combination. 
The human adenosine deaminase acting on RNA (ADAR) protein is an example. ADAR 
was first discovered in Xenopus laevis to have the ability to destabilize dsRNA structure 
(15, 161). It belongs to a family of RNA editing enzymes that catalyze the C-6 
deamination of adenosine (A) to yield inosine (I) in RNA substrates with dsRNA 
character (13, 138, 202). Because inosines are read as guanosines (G) during translation, 
ADAR editing activity can lead to codon changes in mRNA that subsequently alters 
protein function (109, 175). ADAR has two types of A-to-I editing processes: the first 
one is highly site-selective with the adenosine deamination occurring at one or very few 
specific A's in an RNA while the second one can occur at multiple adenosines in RNA 
substrate with stable duplex structure (13, 70, 138, 202).There are three members of the 
ADAR gene, ADAR1, ADAR2, and ADAR3 (13, 14, 65, 114, 138, 202) of which 
ADAR3 lacks the deaminase enzymatic activity (40, 123). Although ADAR2 is 
ubiquitously expressed in most tissues (123), it is most abundant in brain tissue (122). Its 
editing activity is primarily isolated to cellular pre-mRNA because of its nuclear 
localization (51, 173). Furthermore, ADAR2 editing activity has not been reported for 
viral RNA. 
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 ADAR1 is the most studied member of the ADAR family. There are two forms of 
ADAR1 due to alternative promoters (148), the constitutively and ubiquitously expressed 
p110 and the IFN inducible p150 (66, 149). Both forms of ADAR1 consist of a C-
terminal deaminase catalytic domain, three dsRNA binding motifs, RI, RII and RIII, in 
the central region (148, 170). However, the p150 form possesses two Z nucleic acid 
binding domain (Z-NA-BD), Zα and Zβ, while the p110 only has a Zβ domain (76, 148, 
174) (Figure 1). The p150 form has been found shuttling between the cytoplasm and the 
nucleus (56, 62, 156, 191) whereas the p110 form is found predominantly in the nucleus 
(148); therefore, the A-to-I editing by p150 might occur in both cytoplasm and the 
nucleus while p110’s editing activity might occur only in the nucleus. The A-to-I editing 
activity of ADAR1 has been reported in various RNA viruses such as measles virus (35), 
human parainfluenza virus (136), respiratory syncytial virus(117), influenza virus (200), 
lymphocytic choriomeningitis virus (LCMV) (225), Riff Valley virus (192), mumps virus 
(36), hepatitis C virus (198), and HIV (54) and a DNA virus, mouse polyoma virus (95). 
A-to-I viral RNA editing has been shown to have a proviral effect in certain RNA viruses 
such as measles virus (201) and HIV (42, 54, 154), and an antiviral effect in some RNA 
viruses such as influenza (200, 209), LCMV (225), and hepatitis C virus (198). Our 
previous data suggested that there is an IFN-inducible protein that can inhibit late eIF2α 
phosphorylation in vaccinia virus infection (99); we hypothesized that ADAR1 is the 
responsible protein for this phenomenon. We explored the role of ADAR1 in VACV, an 
Orthopox DNA virus, in Chapter 2. 
 The genus Orthopoxvirus is one of the 8 genera of the Poxviridade family (131). 
The Orthopoxvirus genus is the most studied of the poxvirus family due to the variola 
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virus (VARV), the causative agent of smallpox, being a member of this genus. Smallpox 
has been eradicated since 1980 (212) due to vaccination, a concept that was first 
introduced by Edward Jenner who discovered that cowpox virus could be used 
successfully to protect humans against smallpox (164). The vaccination concept is based 
on the foundation that members of this genus are antigenically related, so exposure with 
any orthopoxvirus can protect against exposure with any other orthopoxvirus. Since the 
19th century, another member of this genus has replaced cowpox as a vaccine for 
smallpox, vaccinia virus. VACV is now the most widely studied and prototypic poxvirus. 
Poxviruses are a family of large brick-shaped, enveloped, double stranded DNA 
viruses that have a wide host-range and can infect both vertebrates and invertebrates 
(131, 132). Unlike other DNA viruses, poxviruses replicate entirely in the cytoplasm of 
the infected cells (131). Poxviruses’ genome can vary from about 134kb to more than 300 
kb and has a hair pin loop of inverted terminal repetitions that connect the two DNA 
strands (12, 64). The genome encodes for about 200 proteins in which nearly 100 genes 
are conserved among the members (204). These genes are involved in viral replication 
and are general located in the center of the genome (204). In contrast, genes that locate in 
the termini of the genomes are less conserved, but play a critical role in virus-host 
interactions such as the ability to evade host immune responses. Since different 
poxviruses have different immune evasion genes, it has been suggested that these genes 
were acquired during poxvirus-host adaptation (177). 
Like any other poxvirus, VACV encodes several immune evasion genes in order 
to suppress the host innate immune system, especially the IFN system. Thus, VACV has 
an IFN resisting phenotype. These proteins can inhibit the action of IFN by preventing 
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IFN from binding to its natural receptor, or blocking the virus-induced IFN production 
signaling cascade. Two VACV proteins have been identified to prevent the binding of 
IFNs to their receptors: B19R and B8R (3, 6, 187). The B19R gene, or B18R in Western 
Reserve (WR) strain, encodes for an early expressed 60-65 kilo Dalton (kDa) IFN-α/βR-
like glycoprotein that shares significant homology to cellular IFN-α/βRs (44) and can 
bind and inhibit type I IFN, specifically (3). The protein can bind to human type I IFN 
with high affinity (108) but only binds to mouse type I IFN with low affinity (193). The 
protein can be secreted off the cells or can be embedded on the cell surface of infected 
cells (3, 203). There are VACV strains that do not express B19R such as VACV strains 
Lister and modified vaccinia virus Ankara (MVA), and some strains express a truncated 
version of B19R with a greatly reduced affinity for type I IFN, such as Wyeth strain or 
ACAMBIS2000® strain (ACAM2000®) (193). B19R has been categorized as a virulent 
gene because virus lacking B19R is attenuated in both intranasally and intracranially 
infected mice despite the fact that it binds to mouse IFN with low affinity (44, 193). 
The B8R gene encodes an early expressed 43 kDa glycoprotein that share 
homology to the lunar domain of the type II IFNR and can bind and inhibit type II IFN 
(4). Unlike B19R protein, B8R protein is only secreted from infection cells as a 
homodimer (4). Even though it has a broad specificity to type II IFNs from human, cow, 
rat, rabbit and horse, it cannot bind and inhibit mouse type II IFN (5, 133, 134, 194). The 
virulent factor of B8R has yet to be determined due to conflicting data. Originally, 
deletion of B8R resulted in an attenuated virus in the rabbit model (188). However, 
deletion of B8R showed no difference in virulence in the mouse model (194) but another 
report has shown that deletion of B8R resulted in an attenuated virus in an intranasally 
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infected mouse model (207). Due to their functions, both B19R and B8R have been 
deleted out in several VACV vaccine vectors as a way to improve their immunogenicity 
(92). 
In addition to blocking the IFN signaling by preventing the binding of IFNs to 
their receptors, VACV can inhibit the IFN signaling cascade of TLRs and RLRs which 
induce the production of IFNs upon detection of viral PAMP. The most common PAMP 
produced by VACV is dsRNA (45). Like any other DNA viruses, VACV makes dsRNA 
as a consequence of transcription of genes from both strands of the genome (55). In 
VACV, termination of intermediate and late transcription lacks control, resulting in 
several long run-on intermediate/late transcripts that have heterogeneous 3’ ends and are 
longer than the expected transcript (16). These transcripts can hybridize with early 
transcripts or other intermediate/late run-on transcripts from genes encoded on the 
opposite strand of the DNA to form dsRNA which leads to signaling through TLR and 
RLR. VACV genes have been identified to encode proteins that block the upstream and 
downstream pathways of TLR/RLR signaling such as A46R (189), A52 (26), and K7 
(84). These proteins have been shown to target the MyD88/TRIF/TRAF pathway (26, 73, 
84, 189) and TBK1/IKKε pathway (84). 
VACV also encodes a set of immune evasion genes that can inhibit the 
intracellular action of IFN to induce an antiviral state. These proteins, in particular, are 
the products of the E3L, H1L, and K3L genes. The H1L gene encodes the phosphatase 
VH1, which has been shown to dephosphorylate STAT1 and STAT2 (116), key 
components of the ISGF3 which induce transcription of several antiviral ISGs. The E3 
and K3 proteins are intracellular proteins that block the action of the IFN-induced PKR 
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and OAS activated by dsRNA (49). Activation of these proteins leads to inhibition of 
both viral and cellular protein synthesis in infected cells as described above. K3L encodes 
for an early 10.5 kDa protein that act as a pseudo-substrate of PKR to inhibit 
phosphorylation of eIF2α (20, 32), hence allowing viral protein synthesis. K3L is 
responsible for the IFNR phenotype of VACV and expression of K3L in 
encephalomyocarditis virus (ECMV), an IFN sensitive virus (IFNS), infected cells can 
rescues the virus from the antiviral effect of IFN (181). VACV deleted of K3L (VACV 
ΔK3L) is IFNS (20). 
In contrast to K3L, VACV E3 protein blocks IFN actions by sequestering dsRNA 
and prevents the activation of PKR and OAS (39, 166) and possibly the TLR and RLR 
signaling cascade. The virulent E3L gene encodes for two early proteins, p25 and p20. 
These proteins share homology to the family of dsRNA binding proteins. The full length 
p25 form of E3L is a 190 amino-acid-long protein that consists of two separate domains, 
an N-terminal Z-NA-BD and a C-terminal dsRNA-BM (29) that resemble those of 
ADAR1 as described above. The truncated p20 form of E3L is missing the first 37 amino 
acids from the N-terminus due to leaky scanning and translation initiation at a second 
downstream start codon (39). E3L has been conferred to the IFNR phenotype of VACV. 
Expression of E3 in infected cells with vesicular stomatitis virus (VSV), an IFNS virus, 
can rescue the virus from the antiviral effect of IFN (181). E3L is also necessary for the 
broad host-range phenotype of VACV and contributes to VACV pathogenesis. VACV 
deleted of E3L (VACVΔE3L), is IFN sensitive in both human and rabbit cell lines (10, 
17, 38), has a restricted host range (17, 19, 38), and is greatly reduced in pathogenesis 
(29). In mouse models, VACVΔE3L is apathogenic in both intranasal and intracranial 
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models (29). In cell in culture system, VACVΔE3L results in the activation of PKR and 
OAS by dsRNA, hence inhibiting viral and cellular protein synthesis in HeLa cells. It can 
also lead to cellular induced apoptosis in HeLa cells while wild type VACV (VACV wt) 
does not (103). 
Several studies have been done to map the IFNR ability, PKR inhibition, and 
pathogenesis to the two domains of E3 (Figure 2). VACV pathogenesis in C57BL/6 
mouse model has been mapped to both N-terminal and C-terminal regions of the gene 
(28, 29). Even though the C-terminal dsRNA-BD of E3 was originally thought to be 
responsible for inhibition of PKR and IFN resistance (10, 38), new evidence has 
suggested that the N-terminal Z-NA-BD is also necessary for inhibition of PKR and IFN 
resistance both in mice and in mouse embryonic fibroblasts (MEFs) (99, 215). The host-
range phenotype of E3L has been mapped to the C-terminal also (17, 19, 38), but recent 
studies in our lab have shown that deletion of the Z-NA binding domain, or any mutation 
of the N-terminal, can result in a narrow host range phenotype in JC murine 
adenocarcinoma cell line (Trainor and Jacobs, in preparation). More domains have been 
identified within E3 besides the Z-NA-BD and dsRNA-BD. Within the dsRNA-BD of E3 
there are certain amino acids, which are not required for dsRNA binding, can bind 
directly to PKR (166, 180), suggesting that E3 can inhibit PKR directly. There is also a 
domain from amino acid 117 to 164 that can inhibit IRF3 phosphorylation independent of 
dsRNA-BD (Blattman and Jacobs, in preparation). Taken together, VACV E3L protein 
plays a critical role in VACV’ evasion of the innate immune system, especially the IFN pathway, 
by sequestering dsRNA and inhibiting PKR, OAS and IRF3 pathway (Figure 3). 
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Following the eradication of smallpox, VACV has been developed as a vaccine 
vector for several pathogens. This is feasible due to the fact that it is relatively easy to 
generate recombinant VACVs expressing heterologous genes (130, 145). VACV has 
been proven to be an efficient vaccine vector due to its successful use as a rabies vaccine 
to eliminate rabies in wild animals in parts of the United States and Europe (31, 146, 
147). Therefore, it is logical to develop VACV as a vaccine vector for human pathogens, 
such as HIV. 
The human immunodeficiency virus is a lentivirus in the retroviridae family, and 
is the cause of the acquired immunodeficiency syndrome (43, 213), a condition in which 
an individual’s immune system is progressively weakened to the extent that common 
opportunistic infections (O.Is) can thrive, and the individual succumbs to these O.Is. 
Since its emergence in 1981, HIV has become a pandemic affecting human life in several 
aspects. Even though anti-retroviral therapy has successfully improved HIV patients’ 
lives, according to the World Health Organization, as of 2011, there are 34.0 million 
people living with AIDS. Thus, the need of an HIV vaccine is unquestionable. 
VACV virus has substantial support to be used as an HIV vaccine candidate since 
the HIV trial in Thailand (163). Although VACV has great potential as a vaccine vector, 
safety issues have been the universal concern in VACV-based vaccine development due 
to complications associated with VACV vaccination such as eczema vaccinatum (in 
patients with a history of eczema or atopic dermatitis), generalized vaccinia, and 
progressive vaccinia (in immunocompromised individuals) (96, 97, 124, 160). Several 
VACV strains have been developed by attenuation to be used as a vaccine such as 
ACAM2000®, the second generation and current smallpox vaccine (71), MVA (120), 
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and NYVAC (197). Both ACAM2000® and MVA were attenuated through serial 
passage in Vero cells (71) and chicken embryonic fibroblast cells (120) in culture 
respectedly. In contrast, NYVAC is attenuated through genetically deletion of 18 open 
reading frames (ORFs) from the VACV Copenhagen (VACV COP) strain (197). The 
deleted genes include a cassette of 12 ORFs spanning C7L through K1L, in which C7L 
and K1L are host range genes. Thus, NYVAC is highly attenuated in human cell lines. 
Therefore, NYVAC is one of the best candidates for a safer VACV vaccine vector for 
HIV. 
NYVAC attenuation is due to its inability to replicate in human cell lines. In non-
permissive cells, NYVAC stops at early stages of its replication cycle (137). Thus, it is 
likely that the amount of antigen accumulation during virus infection may not be enough 
to elicit a high immune response. Thus, it is likely that the efficacy of these viruses is 
limited. To improve the NYVAC vaccine vector, our lab, in collaboration with the 
Poxvirus T Cells Discovery Consortium (PTVDC), designed a replication-competent 
NYVAC expressing the HIV antigen. In addition, we genetically deleted out VACV 
B19R, the IFNα/βR like protein, to further improve the efficacy of NYVAC vaccine 
vector. This work will be discussed in Chapter 3. 
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CHAPTER 1 
THE ROLE OF PROTEIN KINASE R AND THE STRESS-ACTIVATED PROTEIN 
KINASE/C-JUN NH2-TERMINAL KINASE IN ACTIVATION OF INTERFERON 
REGULATORY FACTOR 3 
ABSTRACT 
 The interferon regulatory factor 3 (IRF3) and the cellular antiviral protein kinase 
R (PKR) are both activated by double stranded RNA (dsRNA) and play important roles 
in the host innate immune response. Activation of PKR leads to the phosphorylation of 
eIF2α, inhibiting protein synthesis. Activation of IRF3 increases the production of type I 
interferons (IFNs), potent antiviral cytokines. Vaccinia virus (VACV) dsRNA binding 
protein, E3, can prevent both activation of IRF3 and PKR. It has been suggested that 
PKR also plays a role in activation of IRF3. Here, we confirmed the role of PKR in 
activation of IRF3 during VACVΔE3L infection. We then further investigated if 
activation of IRF3 by PKR is signaled through the mitogen activated protein kinases 
(MAPKs). The inhibition of p38 activation did not inhibit the activation of IRF3 while 
the inhibition of the stress-activated protein kinase/ c-Jun NH2-terminal kinase 
(SAPK/JNK) activation inhibited the activation of IRF3. Further characterization data 
showed that PKR-dependent activation of IRF3 in VACVΔE3L requires the 
phosphorylation of IRF3 at Serine 173 by SAPK/JNK. This suggests that PKR is 
necessary but not sufficient to lead to activation of IRF3, and that PKR activates IRF3 via 
SAPK/JNK. 
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INTRODUCTION 
 Type I IFNs (IFNα/β) are cytokines of the innate immune system known to inhibit 
virus replication. They also modulate the adaptive immune response in addition to 
establishing an innate antiviral state (25, 102). IFNs induction occurs when infected cells 
are alerted of viral infection by the presence of dsRNA, a byproduct of many viruses 
(81). The induction of IFNs can occur within hours of virus infection unless protein 
synthesis is inhibited (9). DsRNA can be detected by RIG-I/MDA5, pathogen recognition 
proteins of the RLR system, which trigger the activation of TBK-1 and IKKε through 
TRAF3 and mitochondrial adapter protein IPS1 (75, 169, 179). Activated IKKε 
subsequently phosphorylates IRF3 at the C-terminal serine/threonine cluster between 
amino acids 396 and 405 (60). Following these phosphorylations, IRF3 is associated with 
the cAMP-response element-binding (CREB) protein, resulting in the second 
phosphorylation at serines 385 and 386, leading to the formation of IRF3 homodimer 
(144). Ultimately, activated IRF3 translocates into the nucleus (157) and binds to the 
positive regulatory domain of the IFN promoter, resulting in the expression of type I 
IFNs. 
 IFNs can stimulate production of hundreds of ISGs upon binding to their specific 
receptors (IFNα/β-R) located on the cells’ surface via the signaling cascade of the 
JAK/STAT pathway (23, 25, 48, 50, 105, 190). Some of these ISGs, such as PKR, serve a 
function to prime the cells into an antiviral state (171). The PKR protein, which is also 
constitutively expressed in cells, consists of two N-terminal regulatory domains that bind 
to dsRNA and a C-terminal kinase catalytic domain (127). Upon binding to dsRNA, PKR 
undergoes dimerization and autophosphorylation to become an active protein kinase (41, 
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119, 121). Activated PKR subsequently phosphorylates the α subunit of eIF2 complex, a 
key component of the translational machinery (112). In its normal state, the eIF2 complex 
is inactive in its complex with GDP. With the help of the eIF2B, the guanine nucleotide 
exchange factor, eIF2 exchanges GDP to GTP, resulting in the binding of methionine 
transfer RNA to the 40S ribosomal subunit, hence initiation of protein synthesis (77). 
However, phosphorylation of eIF2α blocks the exchange of GDP to GTP, thus inhibiting 
cellular protein synthesis. Ultimately, virus induced activation of PKR can lead to global 
protein synthesis shut off in order to inhibit virus survival. 
 In addition to eIF2α, PKR has also been reported to interact with other stress 
signaling pathways in response to viral infection such as the p38 and SAPK/JNK 
pathway (8, 69, 79, 195). Both p38 and SAPK/JNK belongs to the MAPK family that 
responds to several cellular stress stimuli such as UV, osmosis stress, viral infection and 
mitogens. These MAPK proteins regulate several cellular function such as cellular 
proliferation, differentiation, apoptosis, etc (151). Both p38 and SAPK/JNK can lead to 
induction of several pro-inflammatory cytokines via the activation of their downstream 
target ATF2 and c-Jun respectively (88, 110). Both ATF2 and c-Jun with IRF3 and NF-
κB can form an enhanceosome complex that activates IFN-β gene transcription (143). 
This implicates that PKR, in conjunction with p38 and SAPK/JNK, might play a role in 
the IFN-induction signaling cascade. 
 Several viruses have evolved mechanisms to evade PKR activation and the 
interferon system (63, 98). VACV is a DNA virus that produces dsRNA in the infected 
cells due to overlapping of convergent intermediate and late transcriptions (81, 211). To 
counter the effect of dsRNA, VACV encodes the E3L gene for an early expressed 
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dsRNA-binding protein that can sequester dsRNA made by VACV, hence inhibiting 
activation of PKR (17, 39, 210). The E3 protein also interferes with the innate immune 
system by blocking the activation of IRF3 and IRF7 (100, 186, 219).VACVΔE3L, 
VACV deleted of E3L gene, is IFN sensitive and has a narrow host range in cell in 
culture (10, 17-19, 38). This is a result of inhibition of protein synthesis induction of 
apoptosis in infected cells (93) and the activation of IRF3, resulting in the activation of 
the innate immune response. 
 PKR has been reported to play a role in regulating IFN-β production in response 
to dsRNA (53, 67). By using PKR-stably-knocked-down HeLa cell lines, it was 
suggested that activation of PKR can lead to activation of IRF3 through IPS1 (228). To 
confirm this finding, we utilized VACVΔE3L expressing a pseudo-substrate of PKR, the 
Ambystoma tigrinium virus’ vIF2 homolog that shares homology to eIF2 (58, 224) and 
we transiently overexpressed a dominant negative form of PKR in VACVΔE3L infection. 
Our results agreed with the previous finding that PKR is necessary for virus induced 
activation of IRF3. Since PKR has been reported to activate p38 and SAPK/JNK (227), 
this led us to examine the role of p38 and SAPK/JNK in the PKR-depdendent-activation 
of IRF3. Our results indicate that SAPK/JNK, not p38, is involved in PKR-dependent-
activation of IRF3. It was reported that SAPK/JNK phosphorylates the N terminal of 
IRF3 at serine 173 (226); thus, we hypothesized that the phosphorylation of IRF3 at 
serine 173 is necessary for the PKR-dependent-activation of IRF3 in VACVΔE3L 
infection.  
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MATERIALS AND METHODS 
 Cells and viruses. Rabbit kidney cells stably expressing VACV E3 protein 
(RK-E3L) were maintained in Eagle’s Minimum Essential Medium (MEM) (Cellgro) 
supplemented with Tetracycline-free 5% fetal bovine serum (FBS) (Thermo Fisher). 
Baby hamster kidney (BHK-21), Rabbit Kidney (RK)-13 cells were maintained in 
Eagle’s MEM (Cellgro) supplemented with 5% FBS (HyClone). HeLa and BSC40 cells 
were maintained in Dulbecco’s Modified-Minimal Essential Medium (DMEM) (Cellgro) 
supplemented with 5% FBS. All cells were incubated at 37°C in the presence of 5% CO2. 
The VACV Copenhagen strain herein is referred to as wild type VACV (VACV wt). 
VACV Copenhagen strain deleted of the E3L gene, VACVΔE3L was generated as 
previously described (38). VACV Copenhagen strain expressing the vIF2αh in the E3L 
locus, VACVΔE3L::viF2αh was generated as previously described (Tripuraneni and 
Jacobs, in preparation). 
 Expression of dominant negative hPKR. pDeNyMCS (empty vector) and the 
dominant negative (DN) pDeNY-hPKR plasmid, which expresses human PKR lacking 6 
amino acids (361-366) between catalytic domains IV and V which render DN-hPKR 
unable to autophosphorylate or activate substrate proteins, were purchased from 
Invivogen. The plasmids were transformed into OneShot®TOP10 chemically competent 
E. Coli cells (Invitrogen). Transformed bacteria were cultured in Terrific Broth 
containing Zeocin at 50 μg/ml. Plasmids were isolated from bacteria using the Maxi Prep 
Kit (Qiagen). Plasmids were transfected into HeLa cells using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instruction. After 48 hours post transfection, the 
transfected cells were infected with VACV wt and VACVΔE3L at multiplicity of 
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infection (MOI) of 5. The cells were lysed with 1X SDS buffer after 6 hours post 
infection. 
 Plasmid construction. pcDNA-V5-IRF3 plasmids were constructed by Dr. 
Saumen Sarkar, and were acquired through Addgene. pcDNA-V5-IRF3 were then used in 
whole plasmid PCR using IRF3S173A F primer (5’ CTGCGGGCTCCCAGCTTGGAC 
3’), IRF3S173A R primer (5’ GCTGGGAGCCCGCAGGGGCTGAG 3’), dNTPs 
(Promega) and Platinum Pfx Polymerase (Invitrogen) to generate pcDNA-V5-IRF3-
S173A which prevents the phosphorylation of IRF3 at the N-terminal. Mutated DNA 
product was transformed into One Shot® TOP 10 chemically competent E. Coli 
(Invitrogen) according to manufacturer’s instructions and incubated on ampicillin coated 
LB agar plates at 37oC overnight. Isolated colonies were selected; plasmid DNA was 
extracted using the PureYieldTM Plasmid MiniPrep System (Promega) and the DNA was 
resuspended in 50 μL nuclease free water (Invitrogen). Plasmid pcDNA-V5-IRF3-S173A 
was sequenced with T7 promoter sequence primer (5’ TAATACGACTCACTATAGGG 
4’) and IRF3 seq primer (5’ ATTTCCGCTCTGCCCTCAAC 3’); and sequence results were 
blasted with the protein sequence of human IRF3 (Uniprot Q14653). 
 Immunoprecipitation assay. Sub-confluent HeLa was transfected with 
either pcDNA-V5-IRF3 or pcDNA-V5-IRF3-S173A plasmids using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instruction. After 48 hours post transfection, the 
transfected cells were infected with VACV wt and VACVΔE3L at multiplicity of 
infection (MOI) of 5. The cells were lysed with RIPA buffer (1% NP40, 0.1%SDS, 0.5% 
Sodium deoxycholate, 100 mM Sodium fluoride, 2 mM Sodium orthovanadate) with 1X 
protease inhibitor (Sigma). Cell lysates were pre-cleared with ProteinA/G bead slurry 
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(Santa Cruz) and normal mouse IgG (Sigma) by rotating for 1 hour at 4oC. The lysates 
were spun down and the supernatants were collected and immunoprecipitated with anti-
V5 antibody (Thermo Fisher) by rotating over night at 4oC. Parts of the supernatants were 
saved for input analysis. The precipitations were pulled down with Protein A/G bead 
slurry and were washed with ice cold RIPA buffer 3 times at 4oC. The 
immunoprecipitation was collected and re-suspended in 30 μL of 2X SDS buffer (100 
mM Tris-Cl pH 6.8, 4% SDS, 0.2% Bromophenol blue, 20% Glycerol, 200 mM β-
Mercaptoethanol). 
 Virus infection.  The virus was diluted in MEM containing 2% FBS. Cell 
monolayers in a 60 mm dishes were infected with 100 μL of virus after aspirating the 
media off the dishes. Cells were incubated at 37oC, 5% CO2 for 1 hour, with rocking 
every 10 minutes. Following infection, the appropriate cell culture media, containing 
DMSO (Sigma), p38 inhibitor SB239063 (Sigma) in DMSO, or JNK inhibitor SP600125 
(Sigma) where indicated, was added. 
Protein extraction and Western Blotting.  50% confluent HeLa cell monolayers 
in 60 mm dishes were infected with viruses at a MOI of 5. Infected cells were incubated 
with DMSO (Sigma), p38 inhibitor SB239063 (Sigma) in DMSO, or JNK inhibitor 
SP600125 (Sigma) where indicated. At 6 hours post infection, cells were scraped into 
150 μL of 1X SDS (62.5 mM Tris-Cl, 10% glycerol, 2% SDS, 0.0005% bromophenol 
blue, 0.1% 2-mercaptoethanol, 1X Halt Protease and Phosphotase Inhibitor Cocktail 
(Pierce Thermo Scientific)). Lysates were transferred into QIAshredder columns 
(Qiagen), spun at 16,000xg for 2 minutes at 4oC, and stored at -80oC. The samples were 
boiled for 5 min and ran on 10% and 12% SDS-PAGE gels at 150V. Proteins were 
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transferred to nitrocellulose membranes at 100 volts for 60 min in 10 mM CAPS, pH 11 
with 20% methanol. The membranes were blocked with 3% milk (Carnation® Non-fat 
Dry Milk) TTBS (20 mM Tris-HCl, pH 7.8, 180 mM NaCl, 0.05% Tween-20) for 1hr. 
The membranes were probed with primary antibodies overnight.  Secondary goat anti-
rabbit IgG conjugated to horseradish peroxidase (1:10,000, Santa Cruz) or anti-mose IgG 
conjugated to horseradish peroxidase (1:10,000, Santa Cruz) was added followed by 
chemiluminescence (Pierce Thermo Scientific). SAPK/JNK antibody, phospho-
SAPK/JNK antibody, p38 antibody, phosphor-p38 antibody, eIF2α antibody, phosphor-
eIF2α antibody, PKR, and IRF3 antibody were purchased from Cell Signaling. GAPDH 
antibody and 6X-His tag antibody were purchased from Abcam. Phospho-PKR antibody, 
phospho-IRF3 at S386 antibody was purchased from Epitomics. 
Protein synthesis shut off assay.  50% confluent HeLa cell monolayers in 60 
mm dishes were infected with VACV wt or VACVΔE3L at a MOI of 5. Infected cells 
were incubated with DMSO (Sigma), p38 inhibitor SB239063 (Sigma) in DMSO, or JNK 
inhibitor SP600125 (Sigma) where indicated. At 5.5 hours post infection, cells were 
washed twice with PBS and were incubated with methionine free DMEM (CellGro) for 
30 minutes. Following starvation for methionine, the cells were incubated for 30 minutes 
with labeling media containing [35S] methionine (50 µCi/mL) (Perkin Elmer). Cells were 
scraped into 150 μL of 1X SDS (62.5 mM Tris-Cl, 10% glycerol, 2% SDS, 0.0005% 
bromophenol blue, 0.1% 2-mercaptoethanol, 1X Halt Protease and Phosphotase Inhibitor 
Cocktail (Pierce Thermo Scientific)). Lysates were transferred into QIAshredder columns 
(Qiagen), spun at 16,000xg for 2 minutes at 4oC, and stored at -80oC. The samples were 
boiled for 5 min and ran on 10% and 12% SDS-PAGE gels at 150V. The gels were 
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stained with staining solution (0.1% Coomassie Brilliant Blue R-250, 40% methanol and 
10% glacial acetic acid) for 15 minutes, then were destained with destaining solution 
(40% methanol and 10% glacial acetic acid) three times, each 15 minutes, and were 
ultimately destained overnight in 10% glacial acetic acid. The gels were then dried and 
exposed to blue film.  
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RESULTS 
 Overexpression of dominant negative PKR inhibits IRF3 phosphorylation at 
S386. To investigate if PKR is necessary for virus induced activation of IRF3 in 
VACVΔE3L, we utilized the overexpression system of dominant negative PKR (DN-
PKR). This dominant negative form lacks 6 amino acids in the kinase domains (361-366) 
resulting in the inability of autophosphorylation of PKR (Figure 4). HeLa cells were 
mock transfected or transfected with either empty vector (pDeNy-MCS) or with vector 
expressing the DN-PKR (pDeNy-hPKR). After 48 hours post transfection, cells were 
mock infected or infected with either VACV wt or VACVΔE3L at a MOI of 5. Cellular 
extracts were obtained at 6 hours post infection and equal volumes of protein were 
analyzed by Western blot probed by specified antibodies. VACV wt, possessing full 
length E3, inhibited both PKR and IRF3 activation among untransfected and transfected 
cells (Figure 5, lane 2, 5, 8). In the untransfected cells and empty vector transfected cells, 
VACVΔE3L led to activation of PKR and IRF3 (Figure 5, lane 3,6), indicated by 
phosphorylation at S386, the phosphorylation site required for activation of IRF3 (144). 
Cells transfected with the DN-PKR leads to an overexpression of PKR that inhibits 
activation of PKR and activation of IRF3 in VACVΔE3L infection (Figure 5, lane 9). 
This suggests that PKR is necessary in activation of IRF3 during VACVΔE3L infection. 
 Recombinant VACV expressing the viral initiation factor 2 α homologue 
inhibits both PKR and IRF3 activation. To further confirm that PKR is necessary in 
activation of IRF3, we utilized the recombinant VACV expressing the viral initiation 
factor 2α homologue (vIF2αh) from the E3L locus. VACV wt was first deleted of E3L 
gene by replacing it with the LacZ gene (38). Then the A57R of Ambystoma Tigrinium 
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virus that encodes the vIF2αh was put into E3L locus, replacing the LacZ gene (Figure 
6A). The vIF2αh protein shares homology to eIF2α in the N-terminal (58, 224) and can 
act as a pseudo-substrate for PKR and specifically lead to degradation of PKR. To ensure 
that we have successfully made VACVΔE3L::vIF2αh, we tagged both E3 and vIF2αh 
proteins with 6X-His tag at the amino terminus of the protein. HeLa cells mock infected 
or infected with VACV wt-His, VACVΔE3L and VACVΔE3L::His-vIF2αh at a MOI of 
5. Cellular extracts were obtained at 3 hours post infection and equal volumes of protein 
were analyzed by Western blot probed with anti-6X His antibody. Expression of E3 was 
observed around 25 kDa while expression of vIF2αh was observed around 35 kDa 
(Figure 6B). 
 To determine if PKR is required for IRF3 activation, HeLa cells were mock 
infected or either infected with VACV wt, VACVΔE3L or VACVΔE3L::vIF2αh. 
Cellular extracts were obtained at 6 hours post infection and equal volumes of protein 
were analyzed by Western blot probed by specified antibodies. As expected, VACV wt 
inhibited both PKR and IRF3 activation (Figure 7, lane 2) while VACVΔE3L led to 
activation of both PKR and IRF3 (Figure 7, lane 3). As a pseudo-substrate for PKR, the 
vIF2αh led to degradation of PKR in the VACVΔE3L::vIF2αh infection. Degradation of 
PKR by vIF2αh prevented the activation of IRF3 (Figure 7, lane 4); thus, combining with 
the above data (Figure 5), PKR is necessary in IRF3 activation during VACVΔE3L 
infection. 
 The specific SAPK/JNK inhibitor, SP600125, but not the specific p38 
inhibitor, SB203580, inhibits PKR-dependent activation of IRF3. It has been 
reported that VACVΔE3L can lead to activation of the MAPK kinase pathway, especially 
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the p38 and SAPK/JNK pathways (227). To determine if p38 or SAPK/JNK is involved 
in PKR-depdent-IRF3 activation, we utilized the specific inhibitor of p38 and 
SAPK/JNK. SB2035880 is known and widely used as a specific p38 inhibitor (57) while 
SP600125 is known and widely used as a specific SAPK/JNK inhibitor (22). HeLa cells 
were mock infected or either infected with VACV wt or VACVΔE3L. Cells were then 
incubated with media containing either DMSO (0.1%), 10μM p38 inhibitor (in DMSO), 
or 10μM SAPK/JNK inhibitor (in DMSO). Cellular extracts were obtained at 6 hours 
post infection and equal volumes of protein were analyzed by Western blot probed by 
specified antibodies. As expected, VACV wt inhibited activation of PKR, p38, 
SAPK/JNK, c-Jun, ATF2 and IRF3 among treated cells (Figure 8, lane 2, 5, 8) while 
VACVΔE3L led to activation of all of these pathways in DMSO treated cells (Figure 8, 
lane 3). In cells treated with p38 inhibitor, VACVΔE3L still led to PKR activation and 
IRF3 activation but failed to fully activate p38 indicating by the low amount of 
phosphorylation of p38 and ATF2 (Figure 8, lane 6). In cells treated with SAPK/JNK 
inhibitor, VACVΔE3L still led to PKR activation but failed to activate either SAPK/JNK 
or its downstream target, c-Jun (Figure 8, lane 9). Interestingly, the SAPK/JNK inhibitor 
led to inhibition of IRF3 activation in VACVΔE3L regardless of the activation of PKR 
(Figure 8, lane 9). This suggests that PKR is necessary to activate IRF3 in VACVΔE3L 
infection but it is not sufficient to activate IRF3 and it requires SAPK/JNK, but not p38, 
activation in order to activate IRF3. 
 The specific SAPK/JNK inhibitor, SP600125, and the specific p38 inhibitor, 
SB203580, do not inhibit virus activity. To determine that the specific p38 and 
SAPK/JNK inhibitor do not affect virus activity, we mock infected or infected HeLa cells 
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with either VACV wt or VACVΔE3L at an MOI of 5 and infected cells incubated with 
media containing either DMSO (0.1%), 10μM p38 inhibitor (in DMSO), or 10μM 
SAPK/JNK inhibitor (in DMSO). Cells were then assayed for protein synthesis by 
labeling with 35S-methione at 6 hours post infection. Either p38 or SAPK/JNK inhibitor 
affected cellular protein synthesis (Figure 9, lane 1, 3, 6). VACV wt led to viral protein 
synthesis among all treated cells (Figure 9, lane 2, 5, 8) while VACVΔE3L led to global 
protein synthesis shut off (Figure 9, lane 3, 6, 9). This suggests that p38 and SAPK/JNK 
inhibitors do not affect virus activity. 
 SAPK/JNK activation is also required for the PKR-dependent activation of 
IRF3 in primary human Keratinocyte. Since keratinocyte is the first layer of cells 
in the human integument system that interacts with VACV during vaccination, we set out 
to determine if the SAPK/JNK is needed for PKR-dependent activation of IRF3 in this 
cell line. Primary human keratinocyte were mock infected or either infected with VACV 
wt or VACVΔE3L. Cells were then incubated with media containing either DMSO 
(0.1%), or 10μM SAPK/JNK inhibitor (in DMSO). Cellular extracts were obtained at 6 
hours post infection and equal volumes of protein were analyzed by Western blot probed 
by specified antibodies. As expected, VACV wt inhibited activation of PKR, SAPK/JNK, 
c-Jun and IRF3 among treated cells (Figure 10, lane 2, 5) while VACVΔE3L led to 
activation of all of these pathways in DMSO treated cells (Figure 10, lane 3). In cells 
treated with SAPK/JNK inhibitor, VACVΔE3L still led to PKR activation but failed to 
activate either SAPK/JNK, c-Jun, or IRF3 (Figure 10, lane 6). This confirms the above 
data (Figure 8) that SAPK/JNK is necessary for PKR-dependent activation of IRF3 in 
VACVΔE3L. 
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Phosphorylation of IRF3 at serine 173 is necessary for activation of IRF3 in 
VACVΔE3L. It has been reported that SAPK/JNK can phosphorylate IRF3 at serine 173 
(S173) at the N terminal (125). To determine if the VACVΔE3L induced activation of 
IRF3  is mediated by SAPK/JNK through phosphorylation of IRF3 at position S173, 
HeLa cells were transfected with pcDNA expressing N-terminal V5-tagged IRF3 
(pcDNA-V5-IRF3) or pcDNA expressing the mutated IRF3 which cannot be 
phosphorylated at position S173 (pcDNA-V5-IRF3-S173A). After 48 hours post 
transfection, cells were mock infected or infected with either VACV wt or VACVΔE3L. 
Cells lysates were prepared after 6 hours post infections and were subjected to 
immunoprecipitation using V5 antibody. The precipitated proteins were analyzed by 
Western blot probed by specified antibodies. VACV wt inhibited IRF3 phosphorylation 
at position S386 in pcDNA-V5-IRF3 transfected cells (Figure 11 Lane 2) and in pcDNA-
V5-IRF3-S173A transfected cells (Figure 11 Lane 5). VACVΔE3L led to large amount of 
IRF3 phosphorylation in pcDNA-V5-IRF3 transfected cells (Figure 11 Lane 3). This 
VACVΔE3L induced IRF3 phosphorylation is subverted in pcDNA-V5-IRF3-S173A 
transfected cells. This suggests that serine 173 of IRF3 is necessary for activation of IRF3 
in VACVΔE3L infection and the PKR-dependent IRF3 phosphorylation is mediated by 
SAPK/JNK phosphorylating IRF3 at S173.  
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DISCUSSION 
The activation of IRF3 by dsRNA has been well established to be a result of the 
signaling cascade of RIG-I/MDA5 and TBK1/IKKε (60, 179). However, more kinases 
have been shown to involve in virus-induced phosphorylation of IRF3 such as 
phosphatidylinositol 3-kinase (107), PKR (228) and the mitogen-associated-protein-
kinase SAPK/JNK (226). In this study, we utilized two methods to confirm the role of 
PKR in the activation of IRF3 in VACVΔE3L infection. We demonstrated that PKR is 
necessary in mediating IRF3 activation; however, it is not sufficient to activate IRF3. We 
found out that SAPK/JNK activation is required for PKR-dependent activation of IRF3. It 
has been reported that the SAPK/JNK kinase phosphorylate IRF3 at the amino terminal at 
serine 173 (226). Using our immunoprecipitation result, we suggest our hypothesized 
working model in which PKR activation leads to SAPK/JNK activation that will 
phosphorylate the amino terminal of IRF3. This will allow confirmation change so that 
IKKε can phosphorylate the carboxyl terminal of IRF3; thus leading to activation of this 
transcription factor (Figure 12). 
Two methods were used to inhibit the PKR pathway: overexpression of the 
dominant negative of PKR and degradation of PKR by Ambystoma Tigrenium viral 
pseudo-substrate of PKR, the viral initiation factor 2α homologue. Overexpression of 
dominant negative of PKR led to inhibition of IRF3 activation, indicated by 
phosphorylation of IRF3 at serine 386, in VACVΔE3L (Figure 5) while 
VACVΔE3L::vIF2αh also inhibited activation of IRF3 because of PKR degradation in 
this viral infection (Figure 7). Thus, it suggests that PKR is necessary for activation of 
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IRF3 in VACVΔE3L infection. This data is in agreement with what was previously 
reported using stably-PKR-knocked-down HeLa (228). 
Since VACVΔE3L can lead to activation of the MAPK kinase pathway, we 
thought that PKR-depdenent-IRF3 activation could be signaled through this pathway. 
Using small molecule inhibitors, we demonstrated that the SAPK/JNK kinase, not the 
p38 kinase, is required for VACVΔE3L induced PKR-dependent activation of IRF3 in 
both HeLa cells (Figure 8) and the physiological relevant human keratinocyte cells 
(Figure 10). Even though we only use small molecule inhibitors to prove our hypothesis, 
these inhibitors are known to be specific only to p38 and SAPK/JNK, and they has been 
widely used and accepted in literature (22, 57). In addition, our data showed that the 
inhibitor did not affect cellular or viral protein synthesis (Figure9). We also attempted to 
transiently knock down SAPK/JNK using siRNA. However, when SAPK/JNK was 
completely knocked down, VACVΔE3L led to more IRF3 phosphorylation compared to 
that of normal cells. Utilizing stably-SAPK/JNK-knocked-out-MEF, we observed the 
same phenomenon. Because SAPK/JNK plays roles in multiple signaling pathways in 
cells, we thought that knock down of SAPK/JNK can result in complementing pathways 
that can induce IRF3 activation in VACVΔE3L. 
Thus, to confirm that SAPK/JNK is necessary for VACVΔE3L induced IRF3 
activation, we utilized immunoprecipitation of V5 tagged IRF3. It has been reported that 
SAPK/JNK phosphorylated IRF3 at the amino terminal at serine 173 (226). Thus, we 
asked whether or not VACVΔE3L can induce activation of IRF3 when S173 cannot be 
phosphorylated. Our results showed that VACVΔE3L can phosphorylate V5-IRF3 but 
not V5-IRF3S173A (Figure 11). This suggests that phosphorylation of IRF3 at serine 173 
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is necessary for IRF3 activation and SAPK/JNK kinase is necessary for VACVΔE3L 
induced PKR-dependent activation of IRF3. Our hypothesized working model is that 
during VACVΔE3L infection, dsRNA will activate PKR which in turn activates 
SAPK/JNK that subsequently phosphorylates IRF3 at serine 173. This will allow 
conformational change of the protein. On the other hand, dsRNA will activate RIG-
I/MDA5 pathway which leads to phosphorylation of IKKε. When IRF3 changes its 
conformation, IKKε will phosphorylate IRF3 at the cluster of threonine 395 and serine 
396. This will allow CREB to phosphorylate IRF3 at serine 386 and IRF3 is activated.  
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Figure 4 – Schematic representation of dominant negative PKR. 
The human protein kinase R is 551 amino acid long and consists of 2 
dsRNA binding domains ((9a.a – 77 a.a) and (100a.a – 167a.a)) and a 
carboxyl terminal kinase domain (267a.a – 538a.a). Dominant negative 
PKR lacks 6 amino acids in the kinase domain (361a.a – 366a.a) that 
results in the DN-PKR’s inability to autophosphorylate and inhibit 
phosphorylation of endogenous PKR.  
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Figure 5 – Overexpression of dominant negative PKR leads to 
inhibition of IRF3 phosphorylation in VACVΔE3L infection. HeLa 
cells were either untransfected or transfected with empty vector 
(pDeNY-MCS) or vector expressing dominant negative PKR (pDeNy-
hPKR). After 48 hours post transfection, cells were either mock 
infected or infected with either VACV wt or VACVΔE3L at an M.O.I 
of 5. Cell lysates were prepared at 6 hours post infection. The proteins 
were resolved on a 10% SDS PAGE gel followed by western blotting 
using above specified antibodies to proteins.  
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Figure 7 – VACV expressing the viral eIF2α homologue inhibits 
IRF3 phosphorylation. HeLa cells were either mock infected or 
infected with VACV wt, VACVΔE3L, or recombinant VACV 
expressing the viral eIF2α homologue from the E3L locus 
(VACVΔE3L::vIF2αh). Cell lysates were prepared at 6 hours post 
infection. The proteins were resolved on a 12% SDS PAGE gel 
followed by western blotting using above specified antibodies. 
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Figure 8 – Inhibition of SAPK/JNK phosphorylation prevent PKR-
dependent-IRF3 phosphorylation. HeLa cells were mock infected or either 
infected with VACV wt or VACVΔE3L. Cells were mocked incubated with 
DMSO or incubated with either p38 inhibitor (SB203580) or SAPK/JNK 
inhibitor (SP600125). Cell lysates were prepared at 6 hours post infection. The 
proteins were resolved on a 10% SDS PAGE gel followed by western blotting 
using above specified antibodies. 
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Figure 9 – Both p38 and SAPK/JNK inhibitors do not affect viral 
protein synthesis. HeLa cells were mock infected or either infected with 
VACV wt or VACVΔE3L. Cells were mocked incubated with DMSO or 
incubated with either p38 inhibitor (SB203580) or SAPK/JNK inhibitor 
(SP600125). Cells were radio-labeled with [
35
S] methionine at 6 hours 
post infection. After 30 minutes of radio-labeled, cell lysates were 
prepared. The lysates were resolved on a 12% SDS-PAGE gel and 
subjected to autoradiography  
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Figure 10 – Inhibition of SAPK/JNK phosphorylation prevent PKR-
dependent-IRF3 phosphorylation in primary human Keratinocyte. 
Primary human Keratinocytes cells were mock infected or either infected with 
VACV wt or VACVΔE3L. Cells were mocked incubated with DMSO or 
incubated SAPK/JNK inhibitor (SP600125). Cell lysates were prepared at 6 
hours post infection. The proteins were resolved on a 10% SDS PAGE gel 
followed by western blotting using above specified antibodies. 
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Figure 11 – VACVΔE3L induced IRF-3 phosphorylation at Serine 386 
requires phosphorylation of the N terminal at Serine 173A. HeLa cells were 
transfected with either pcDNA-V5 IRF3 or pcDNA-V5 IRF3S173A. After 48 
hours post transfection, cells were either mock infected or infected with either 
VACV wt or VACVΔE3L at an M.O.I of 5. Cell lysates were prepared at 6 hours 
post infection. Cell lysates were then immunoprecipitated with V5 antibody.  
Proteins were resolved on a 10% SDS PAGE gel and probed with specified 
antibodies. 
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CHAPTER 2 
THE ROLE OF ADENOSINE DEAMINASE ACTING ON DSRNA 1 (ADAR1) IN 
VACCINIA VIRUS INFECTION 
ABSTRACT 
Adenosine Deaminases Acting on RNA 1 (ADAR1) catalyzes the deamination 
reaction of adenosine to produce inosine in double stranded RNA (dsRNA). ADAR1 has 
been extensively studied during viral infection. The Vaccinia virus (VACV) virulence 
factor E3L and ADAR1 contain both a Z-NA binding domain and a dsRNA binding 
domain that are functionally homologous. ADAR1 is presented in cells both in the 
constitutively expressed form, p110, and the interferon (IFN) induced form, p150. Our 
data showed that when cells were treated with IFN, there was less dsRNA detected in the 
VACVΔE3L infected cells, suggesting this phenomenon might be due to the action of the 
IFN-induced ADAR1 protein. This is correlated with the reduction of eIF2α 
phosphorylation in IFN treated, VACVΔE3L infection. Using a vaccinia virus expressing 
the IFN-induced ADAR1 in VACVΔE3L infection, we demonstrated that ADAR1 
rescued viral protein synthesis and replication of VACVΔE3L. Thus, ADAR1 plays a 
proviral role in VACV infection. This is the first time that the pro-viral role of ADAR1 is 
described.  
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INTRODUCTION 
 Viruses are obligate intracellular parasites that hijack cellular machinery for their 
survival. The interferon (IFN) system of the innate immune response can prime the cells 
into an antiviral state to resist viral infections (80). This antiviral state is a condition in 
which IFNs induce expression of several antiviral proteins such as the dsRNA-activated 
protein kinase R (PKR) and the 2’-5’-oligo adenylate synthetase (OAS) (106, 162, 168, 
185). Both proteins are expressed in inactive forms and are activated upon detection of 
dsRNA, a byproduct made by most viruses during their intracellular life cycles (33, 46, 
104). Activation of PKR leads to phosphorylation of the α subunit of the eukaryotic 
translation initiation factor 2 (eIF2α) which results in the inhibition of protein translation 
initiation, thereby resulting in protein synthesis shut off in infected cells (77, 112). 
Activation of the OAS system leads to activation of RNase L, a latent endoribonuclease. 
Active RNase L can cleave both ribosomal RNA and messenger RNA in the infected 
cells (61), thereby leading to an arrest of protein synthesis (216). 
Several viruses have developed mechanisms to evade the interferon system (63). 
VACV has been shown to resist the antiviral state established by IFNs in most cell lines 
(10, 19). The ability of VACV to resist the antiviral state relies of its virulence factor, the 
E3L gene (39, 219). This virulent gene is necessary for the broad-host-range phenotype 
of VACV (18) and the IFN resistant phenotype (19), and contributes greatly to VACV 
pathogenesis (29). E3L encodes a 25 kDa protein and an N-terminal-37-amino-acid-
truncated p20 kDa protein, both contains a Z-nucleic acid (Z-NA) (Z-formed nucleic 
acid) binding domain (ZNA-BD) in its amino terminus and a dsRNA binding motif 
(dsRNA-BM) in its carboxyl terminus  (29, 39). E3 proteins inhibit both PKR and OAS 
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activation by sequestering dsRNA made during its life cycle in infected cells (37-39, 45, 
165, 182). These inhibitions allow protein synthesis to occur in the infected cells and the 
virus continues to replicate. VACV deleted of E3L (VACVΔE3L) is IFN sensitive (IFNS) 
(10, 17, 38) and has a restricted host range (17, 19, 38) in cells in culture. These 
phenotypes are due to the activations of PKR and OAS. VACVΔE3L is greatly reduced 
in pathogenesis (29). Both the ZNA-BD and the dsRNA-BM have been shown to 
contribute to the broad host range phenotype, the IFN resistance (IFNR) through PKR 
inhibition (99, 215) and neurovirulence in mice (28, 29). Sequence comparison reveals 
that E3L shares homology to several IFN induced dsRNA binding proteins, such as the 
Adenosine Deaminase Acting on dsRNA 1 (ADAR1) protein. 
 ADAR1 is a cellular, IFN inducible protein that belongs to a protein family of 
RNA editing protein that catalyzes the C-6 deamination of adenosine (A) to yield inosine 
(I), in RNA substrates with dsRNA character (13, 138, 202). Because inosine is read as 
guanosine (G) during translation, this A to I editing activity lead to codon change in 
mRNA that, in turn, alters protein function (109, 175).  ADAR1 exists in two forms, the 
constitutively and ubiquitously expressed p110 and the IFN inducible p150 which is 
driven by an IFN inducible promoter (66, 148, 149). Both p110 and p150 consist of a C-
terminal deaminase catalytic domain, and three dsRNA-BMs in the central region (148, 
170); however, the p150 consists of two ZNA-BDs, Zα and Zβ, while the p110 only has 
the Zβ domain (76, 174). Interestingly, the IFN induced p150 of ADAR1 and E3L is very 
similar in the organization of their domains in that both proteins possess the Zα ZNA-BD 
and dsRNA-BMs (111). 
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 The role of ADAR1 has been reported to be both antiviral and proviral in several 
RNA viruses system (170). Here, we investigated the role of ADAR1 in VACV, a DNA 
virus. It has been reported that VACV deleted of the Z-NA binding domain 
(VACVΔ83N) leads to eIF2α phosphorylation during late time infection. However, this 
phenomenon can be inhibited by pre-treatment of IFN (99). Due to the fact that ADAR1 
is IFN inducible and portrays deaminase activity, we hypothesized that ADAR1 
deaminates dsRNA made by VACV leading to the inhibition of late eiF2α 
phosphorylation. Our results indicate that pretreatment of IFN leads to the reduction of 
dsRNA in VACVΔ83N and VACV deleted of E3L (VACVΔE3L) infections. By 
replacing VACV E3L gene with the p150 form of ADAR1, we studied the role of 
ADAR1 in VACVΔE3L infection. Our results indicate that ADAR1 can rescue protein 
synthesis and replication of VACVΔE3L in HeLa cells. However, these phenotypes 
require the deaminase activity of ADAR1. In summary, our data suggests that ADAR1 
plays a proviral role in VACV infection.  
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MATERIALS AND METHODS 
Cells and viruses. Rabbit kidney cells stably expressing VACV E3 protein 
(RK-E3L) were maintained in Eagle’s Minimum Essential Medium (MEM) (Cellgro) 
supplemented with Tetracycline-free 5% fetal bovine serum (FBS) (Thermo Fisher). 
Baby hamster kidney (BHK-21), and Rabbit Kidney (RK-13) cells were maintained in 
Eagle’s MEM (Cellgro) supplemented with 5% FBS (HyClone). HeLa and BSC40 cells 
were maintained in Dulbecco’s Modified-Minimal Essential Medium (DMEM) (Cellgro) 
supplemented with 5% FBS. All cells were incubated at 37°C in the presence of 5% CO2. 
The VACV Copenhagen strain and the VACV Western Reserve (WR) strain herein are 
referred to as wild type VACV (VACV wt). VACV Copenhagen strain or VACV WR 
strain deleted of the E3L gene, VACVΔE3L was generated as previously described (38). 
VACV Copenhagen strain or VACV WR strain deleted of the ZNA-BD of E3L gene, 
VACVΔ83N was generated as previously described (183). VACV WR strain expressing 
the p150 ADAR1 (VACVΔE3L::ADAR1) and the catalytic inactive p150 ADAR1 
(VACVΔE3L::ADAR1m) were generated as previously described (135). 
Reconstruction of pmpADAR1 and pmpADAR1m. The ADAR1 gene 
was amplified out of the WR strain VACVΔE3L::ADAR1 genome using E3L F (5’ 
CGAAACACCAGAGGATG 3’) and E3L R (5’ TAGTCGCGTTAAATAGTACTA 3’) 
primers, dNTPs (Promega) and Platinum Pfx Polymerase (Invitrogen). The PCR product 
was column purified using the Wizard® SV Gel and PCR Clean up Kit (Promega) 
according to manufacturer’s instructions. The PCR product and pmpMCS plasmid were 
digested with HindIII (NEB) according to manufacturer’s instructions. The digested 
pmpMCS vector was then treated with Alkyline Phosphotase (NEB) to remove 5’ 
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phosphate end according to manufacturer’s instruction and then column purified as 
above. Digested ADAR1 product was cloned into digested pmpMCS using T4 DNA 
ligase (NEB) according to manufacturer’s instructions. Ligated DNA was transformed 
into One Shot® TOP 10 chemically competent E. Coli (Invitrogen) according to 
manufacturer’s instructions and incubated on ampicillin coated LB agar plates at 37oC 
overnight. Isolated colonies were selected; plasmid DNA was extracted using the 
PureYieldTM Plasmid MiniPrep System (Promega) and the DNA was resuspended in 50 
μL nuclease free water (Invitrogen). Plasmid pmpADAR1 was screened for proper 
orientation of the cloned genes using BamHI (NEB) enzymes. Corrected orientation 
plasmids of pmpADAR1 were sequenced with E3L F primer, ADAR 1F primer (5’ 
AGACAGAAACTCCACATCTGTCTC 3’), ADAR 2F primer (5’ 
CTCCTTCTACAGTCATGGCTTG), ADAR 3F primer (5’ 
GATGCCCTCCTTCTACAGTC 3’), ADAR 4F primer (5’ 
CCTTTTGGAGTACGCCCG 3’), and ADAR 5F primer (5’ 
TATGGAAAGCACAGAATCCCG 3’); and sequence results were blasted with the 
protein sequence of ADAR1 (Uniprot P55265). pmpADAR1 was then used as DNA 
template in whole plasmid PCR using ADARHQEA F primer (5’ 
GTCAATGACTGCCAGGCAGCAATAATC 3’), ADARHQEA R primer (5’ 
GGGAGATTATTGCTGCCTGGCAGTC 3’), dNTPs (Promega) and Platinum Pfx 
Polymerase (Invitrogen) to generate pmpADAR1m which has two point mutations: 
H910Q and E912A. Mutated DNA product was transformed into One Shot® TOP 10 
chemically competent E. Coli (Invitrogen) according to manufacturer’s instructions and 
incubated on ampicillin coated LB agar plates at 37oC overnight. Isolated colonies were 
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selected; plasmid DNA was extracted using the PureYieldTM Plasmid MiniPrep System 
(Promega) and the DNA was resuspended in 50 μL nuclease free water (Invitrogen). 
Plasmid pmpADAR1m were sequenced with E3L F primer, ADAR 1F primer (5’ 
AGACAGAAACTCCACATCTGTCTC 3’), ADAR 2F primer (5’ 
CTCCTTCTACAGTCATGGCTTG), ADAR 3F primer (5’ 
GATGCCCTCCTTCTACAGTC 3’), ADAR 4F primer (5’ 
CCTTTTGGAGTACGCCCG 3’), and ADAR 5F primer (5’ 
TATGGAAAGCACAGAATCCCG 3’); and sequence results were blasted with the 
protein sequence of ADAR1 (Uniprot P55265). 
Generation of Copenhagen VACVΔE3L::ADAR1 and 
VACVΔE3L::ADAR1m by Coumermycin selection. pmpADAR1 and 
pmpADAR1m were used in the in vivo recombination assay with VACVΔE3L::NeoR-
GFP-GyrB-PKR and recombinant viruses were selected under Coumermycin selection as 
previously described (214). Briefly, sub confluent BHK21 cell monolayers were with 
VACVΔE3L::NeoR-GFP-GyrB-PKR at a multiplicity of infection of 0.05 and 
simultaneously transfected with 1 μg of plasmids using Lipofectamine  (Invitrogen) and 
Plus Reagent (Invitrogen). At 48 hours post infection, infected cells were harvested in 
MEM containing 2% FBS. This was allowed by 3 rounds of freezing at -80oC and 
thawing on ice for 30 minutes to release the virus. The recombinant viruses were selected 
by coumermycin at 10ng/ml concentration in RK-13 cells for 3 rounds. The recombinant 
viruses were sequenced to determine the correct sequence of ADAR1 and ADAR1m 
containing the H910Q and E912A mutation in the E3L locus of VACV. Expression of 
ADAR1 and ADAR1m were confirmed by Western Blotting. 
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Sequencing of the ADAR1 gene from the recombinant virus.  100 µL of virus 
stock with a titer of 1x109 pfu/mL was used for DNA extraction.  Virus DNA was 
extracted by treating the virus with a 100 μL of phenol equilibrated with 10 mM Tris 
HCl, pH 8.0, 1 mM EDTA (Sigma).  The aqueous phase from the above step was re-
extracted with 100 μL phenol:isoamylalcohol:chloroform (25:24:1) (Sigma). The aqueous 
phase from the above step was re-extracted with 100 μL volume 
chloroform:isoamylalcohol (24:1) (Sigma), followed by precipitation with 2.5 volumes of 
95% ethanol, 1/10 volume of 7.5M ammonium acetate, and 10μL glycogen (Fermentas). 
The DNA was washed in 70% ethanol, dried and resuspended in 50 µL of distilled water. 
PCR was performed using E3L flanking primers to amplify the gene for 
sequencing.  Briefly, 100 ng of virus DNA template, 500 μM of E3L F,  500 μM of E3L 
R, 500 μM dNTPs, 2 mM MgSO4, 1X Pfx buffer, 1X Enhancer and Platinum pfx 
polymerase enzyme (Invitrogen) were mixed in a 50 µL reaction volume.  PCR 
amplifications were performed with 95ºC for 5 minutes, followed by 30 cycles of 
amplification (95ºC for 1 minute, 55ºC for 1 minute, 68ºC for 5 minutes).  The PCR 
product was subjected to agarose gel electrophoresis (0.8%, GTG grade) at 100 volts for 
40 minutes, and the DNA band was cut from the gel.  DNA was extracted from the gel 
using Wizard® SV Gel and PCR Clean up Kit (Promega) according to the 
manufacturer’s instructions, and sequenced using ADAR 1F primer (5’ 
AGACAGAAACTCCACATCTGTCTC 3’), ADAR 2F primer (5’ 
CTCCTTCTACAGTCATGGCTTG), ADAR 3F primer (5’ 
GATGCCCTCCTTCTACAGTC 3’), ADAR 4F primer (5’ 
CCTTTTGGAGTACGCCCG 3’), and ADAR 5F primer (5’ 
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TATGGAAAGCACAGAATCCCG 3’); and sequence results were blasted with the 
protein sequence of ADAR1 (Uniprot P55265). 
Virus infections and stocks. BHK-21 cells were used to amplify the recombinant 
viruses. Stocks of recombinant viruses were generated by amplification of a single 
corrected plaque in 60 mm dish of BHK-21 cells. At 100% cytopathicity, the infected 
cells were harvested by scraping and centrifuging at 1000 rpm for 10 minutes at 4oC. The 
cell pellet was resuspended in 10 mM Tris HCl pH 8.8. Three round of alternate freezing 
(-80oC) and thawing on ice for 30 minutes, followed by vortexing for 30 seconds (3 
times) was performed to lyse the cells and release the virus. The prep was then spun at 
1000 rpm for 10 minutes at 4oC and the virus in the supernatant was transferred into a 
fresh tube and stored at -80oC. The virus was titered in RK-E3L cells. 
 For infections, the virus was diluted in MEM containing 2% FBS. Cell 
monolayers in a 60 mm dishes were infected with 100 μL of virus after aspirating the 
media off the dishes. Cells were incubated at 37oC, 5% CO2 for 1 hour, rocking every 10 
minutes. Following infection, the appropriate cell culture media was replaced. 
 Protein extraction and Western Blotting.  50% confluent HeLa cell 
monolayers, pretreated with 1,000 IU/ml of human α A/D interferon (PBL) for 18 hours 
where indicated, were infected with viruses at a MOI of 5. At the indicated times post 
infection, cells were scraped into 150 μL of 1X SDS (62.5 mM Tris-Cl, 10% glycerol, 
2% SDS, 0.0005% bromphenol blue, 0.1% 2-mercaptoethanol, 1X Halt Protease and 
Phosphotase Inhibitor Cocktail (Pierce Thermo Scientific)). Lysates were transferred into 
QIAshredder columns (Qiagen), spun at 16,000xg for 2 minutes at 4oC, and stored at -
80oC. The samples were boiled for 5 min and ran on 10% and 12% SDS-PAGE gels at 
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150V. Proteins were transferred to nitrocellulose membranes at 100 volts for 60 min in 
10 mM CAPS, pH 11 with 20% methanol. The membranes were blocked with 3% milk 
(Carnation® Non-fat Dry Milk) TTBS (20 mM Tris-HCl, pH 7.8, 180 mM NaCl, 0.05% 
Tween-20) for 1hr. The membranes were probed with primary antibodies overnight.  
Secondary goat anti-rabbit IgG conjugated to horseradish peroxidase (1:10,000, Santa 
Cruz) or anti-mose IgG conjugated to horseradish peroxidase (1:10,000, Santa Cruz) 
were added followed by chemiluminescence (Pierce Thermo Scientific). ADAR1 
antibody was purchased from Santa Cruz, eIF2α-P antibody was purchased from Cell 
Signaling, dsRNA antibody was purchased from Engscions, and GAPDH antibody was 
purchased from Abcam. 
Immunofluorescence Microscopy.  HeLa cells were seeded on poly L- lysine 
treated coverslips in 6 well dishes. HeLa cell monolayers, pretreated with 1,000 IU/ml of 
human α A/D interferon (PBL) for 18 hours where indicated, were infected with viruses 
at a MOI of 5. At indicated time points, the cells were rinsed twice with cold PBS.  
Subsequently, ice cold methanol was added and the cells were placed at -20ºC for 20 
minutes.  The cells were then washed twice with ice cold PBS and blocked with blocking 
buffer (0.3% gelatin, 0.1% triton X-100 in PBS) at room temperature for 30 minutes.  
The cells was incubated with prepared primary antibody: mouse anti-dsRNA (Engscions) 
and rabbit anti-VACV, diluted in 0.1% triton x-100 in PBS, overnight at 4°C.  The cells 
were then washed five times with blocking buffer for 10 minutes per wash.  The cells was 
incubated with prepared secondary antibodies:anti-rabbit IgG Alexa Fluor 488 and anti-
mouse IgG Alexa Fluor 594 (Invitrogen), diluted in blocking buffer, for 1 hour at room 
temperature in the dark.  After incubation, the cells were washed 3 times with blocking 
55 
 
buffer for 10 minutes per wash.  4’6diamino-2-phenylindole (DAPI) (Invitrogen) was 
added at a concentration of 5 µg/mL for 5 minutes at room temperature in the dark.  The 
cells were rinsed with ddH2O and then mounted onto slides with ProLong Gold antifade 
mounting reagent (Invitrogen).  The samples were allowed to cure overnight.  Samples 
were analyzed using the EVO-FL microscope (AMG). 
Slot Blot for dsRNA.  50% confluent HeLa cell monolayers, pretreated with 
1,000 IU/ml of human α A/D interferon (PBL) for 18 hours where indicated, were 
infected with viruses at a MOI of 5. At time indicated, total RNA was extracted from 
using the RNeasy Mini Kit (Qiagen). 100 ng to 1 μg of total RNA was diluted in 1mM 
EDTA, pH 8.0 to a final volume of 50 μL.  Hybond-N+ (Amersham Pharmacia Biotech) 
positively charged membrane was soaked in ddH2O and then in 10X SSC (Amersham 
Pharmacia Biotech). Diluted RNA was applied through a VacuSlot VS manifold and 
transferred onto membrane under vacuum. Membrane was washed twice with 10X SSC 
buffer. The membrane was UV crosslinked with a Stratagene Stratalinker 1800 
(Stratagene) for 90 seconds. Western blot analysis was performed with J2 monoclonal 
dsRNA antibody (Engscions) for detection of the dsRNA. 
Single-step growth assay. HeLa cells in 6 well plates were infected with MOI 
of 5 with VACV wt, VACVΔE3L, VACVΔE3L::ADAR, VACVΔE3L::ADARm. Plates 
were incubated at 4oC for 30 minutes and rocked every 10 minutes. Plates were washed 
thrice with warm media. Half of the infected cells were harvested for 0 hour time point. 
Plates were incubated at 37oC, 5%CO2 for 24 hours. Infected cells were then harvested 
for 24 hour time point. Samples were frozen and thawed 3 times (frozen at -80oC for 30 
minutes, and then thawed on ice for 30 minutes, followed by 3 minutes thaw at 37oC) to 
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release viruses. Ultimately, samples were spun at 1,000xg for 10 minutes at 4oC and the 
supernatants were collected. Viruses were titered using RK-E3L. The experiment was 
done in triplicate. 
Multi-step growth assay. HeLa cells in 6 well plates were infected with MOI 
of 0.01 with VACV wt, VACVΔE3L, VACVΔE3L::ADAR1, VACVΔE3L::ADAR1m. 
Plates were incubated at 4oC for 30 minutes and rocked every 10 minutes. Plates were 
washed thrice with warm media. Half of the infected cells were harvested for 0 hour time 
point. Plates were incubated at 37oC, 5%CO2 for 72 hours. Infected cells were then 
harvested for 72 hour time point. Samples were frozen and thawed 3 times (frozen at -
80oC for 30 minutes, and then thawed on ice for 30 minutes, followed by 3 minutes thaw 
at 37oC) to release viruses. Ultimately, samples were spun at 1,000xg for 10 minutes at 
4oC and the supernatants were collected. Viruses were titered using RK-E3L. The 
experiment was done in triplicate. 
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RESULTS 
 Pre-treatment of IFN reduces delayed-late time eIF2α phosphorylation.
 It was reported that VACV deleted of the N-terminal of E3L can inhibit eIF2α 
phosphorylation at delayed-late time post infection when the infected cells were pre-
treated with IFN (99). To confirm this, HeLa cells were mock treated or treated with 
1000 U/ml of IFNα/β for 18 hours. Cells were then either mock infected or infected with 
either VACV wt, VACV deleted of the N-terminal of E3L, VACVΔ83N or VACVΔE3L 
at an MOI of 5. As expected mock and VACV wt infected cells showed no detectable 
eIF2α phosphorylation (Figure 13, lane 1, 3 and 9). VACVΔE3L infection led to eIF2α 
phosphorylation at 6 hours post infection (initial-late phase of the infection) and eIF2α 
phosphorylation increased at 9 hours post infection (delayed-late phase of the infection) 
(Figure 13, lane 5 and 11). Infection with VACVΔ83N did not lead to eIF2α 
phosphorylation until 9 hours post infection even though the amount of eIF2α 
phosphorylation was not as high as there were in VACVΔE3L infection (Figure 13, lane 
4 and 10). When cells were pretreated with IFN, VACV wt was still able to inhibit eIF2α 
phosphorylation both at 6 and 9 hours post infection (Figure 13, lane 6 and 12). At 9 
hours post infection, IFN-treated cells infected with VACVΔ83N and VACVΔE3L 
showed decreases of eIF2α phosphorylation compared to those without IFN treatment 
(Figure 13, lane 13 and 14). These results raised the question that if inhibition of the 
delayed-late time eIF2α phosphorylation in VACVΔE3L and VACVΔ83N infection is 
due to decrease in dsRNA made by these viruses. 
 Pre-treatment of IFN reduces dsRNA made by VACV.  Since eIF2α 
phosphorylation is a result of activation of PKR by dsRNA made during VACV 
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infection, we hypothesized that reduction in eIF2α phosphorylation in IFN-treated cells 
infected with VACVΔ83N and VACVΔE3L is due to the decrease level of dsRNA made 
during VACV infection. To test this hypothesis, we employed the use of 
immunofluorescence and slot blotting probing with anti-dsRNA. HeLa cells were mock 
treated or treated with 1000U/ml of IFNs. After 18 hours post treatment, cells were mock 
infected or infected with either VACV wt, VACVΔE3L or VACVΔ83N. The infected 
cells were either fixed for immunofluorescence or harvested for total RNA. For 
immunofluorescence, cells were incubated with antibodies against total VACV proteins 
(anti VACV) and dsRNA. 
The immunofluorescence data showed that dsRNA was detected within infection 
of VACV wt, VACVΔ83N and VACVΔ3L (Figure 14). When the cells were pre-treated 
with IFNs, the amount of dsRNA was not changed in VACV wt infection. Lower amount 
of dsRNA was detected in VACVΔ83N and VACVΔE3L infection when the cells were 
pre-treated with IFN (Figure 14). 
To confirm our immunofluorescence data, a slot blot was performed. 100 ng of 
total RNA were applied onto a positive membrane via vacuumed slots. The RNA was 
then UV-hybridized and blotted with antibody against dsRNA. As expected, mock 
infected cells did not produce any dsRNA (Figure 15, lane 1). VACV wt, VACVΔ83N 
and VACVΔE3L virtually made the same amount of dsRNA (Figure 19, lane 2, 3 and 4). 
When the cells were treated with IFN, the amount of dsRNA in VACV wt did not 
decrease significantly (Figure 19, lane 5). On the other hand, the amount of dsRNA in 
VACVΔ83N decreased about 2 folds while it decreased about 4 folds in VACVΔE3L 
infection (Figure 19, lane 6 and 7). Taken together, both our immunofluorescence data 
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and slot blot data suggested that there are other factors that can decrease the amount of 
dsRNA in VACV infection; thus resulting in inhibition of delayed-late time eIF2α 
phosphorylation in VACVΔ83N and VACVΔE3L. 
 Virus construction. Literature searches to explain the above phenomenon 
focused our attention to the IFN inducible ADAR1 protein. Domain-wise, ADAR1 has 
both ZNA-BD and dsRNA-BMs as VACV E3 protein. Both Zα domain of E3 and 
ADAR1 shares close homology as well as the dsRNA-BMs (Figure 16). In addition, 
ADAR1 possesses a deaminase domain that can denature RNA with double stranded 
character. Thus, we hypothesized that expressing ADAR1 in VACVΔE3L can lead to 
reduction in the amount of dsRNA made by VACVΔE3L and it will rescue VACVΔE3L 
infection in non-permissive cell. To test the hypothesis, we put the IFN-induced full 
length ADAR1 gene into the E3L locus of VACV. We also put a mutant ADAR1 gene 
(ADAR1m) where the protein still retains its ability to bind to dsRNA but it is incapable 
of carrying out the deaminase function because of two point mutations (H910Q and 
E912A) in the catalytic domain (125) (Figure 17A). In order to confirm ADAR1 
expression, sub-confluent HeLa cells were mock infected or infected at MOI of 5 with 
either VACV wt, VACVΔE3L, VACVΔE3L::ADAR1 or VACVΔE3L::ADAR1m. Cell 
lysates were prepared at 6 hours post infection and the proteins were visualized by 
western blotting using antibodies against ADAR1 protein. The full length ADAR1 (a 150 
kDa protein) were detected from the infection of VACVΔE3L::ADAR1 and 
VACVΔE3L::ADAR1m compared to uninfected cells or cell infected with either VACV 
wt or VACVΔE3L. The constitutive form of ADAR1 (a 110 kDa protein) was detected 
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from all lysates (Figure 17B). These results indicated that IFN-induced ADAR1 protein 
was successfully expressed from the E3L locus of VACV. 
 ADAR1 deaminates dsRNA made by VACVΔE3L. To test whether or not 
the IFN-induced ADAR1 protein expressed by VACV can deaminate dsRNA, we 
employed the use of immunofluorescence and slot blotting. HeLa cells were mock 
infected or infected with either VACV wt, VACVΔE3L, VACVΔE3L::ADAR1 or 
VACVΔE3L::ADAR1m. The infected cells were either fixed for immunofluorescence or 
harvested for total RNA. For immunofluorescence, cells were incubated with antibodies 
against total VACV proteins (anti VACV) and dsRNA. Both VACVwt (data not shown) 
and VACVΔE3L led to production of dsRNA in the infected cells. However, when IFN-
induced ADAR1 was expressed from the E3L locus, dsRNA was undetectable using 
immunofluorescence. The inactive catalytic mutant of ADAR1 which cannot deaminate 
dsRNA led to production of dsRNA in the infected cells even though the level of dsRNA 
was not as high as in the VACVΔE3L infection (Figure 18). This low level detection of 
dsRNA might be due to the interaction of the ADAR1 dsRNA-BMs or other cellular 
dsRNA binding proteins where dsRNA blocks the binding affinity of the detection 
antibody against dsRNA. 
To confirm our immunofluorescence data, a slot blot was performed. 100 ng of 
total RNA were applied onto a positive membrane via vacuumed slots. The RNA was 
then UV-hybridized and blotted with antibody against dsRNA. As expected, mock 
infected cells did not produce any dsRNA (Figure 19, lane 1). Both VACV wt and 
VACVΔE3L made dsRNA (Figure 19, lane 2 and 3). VACVΔE3L::ADAR1 infection led 
to a 7 fold decrease in dsRNA (Figure 19, lane 4). The decrease in dsRNA correlated 
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with the ability to deaminate dsRNA because VACV expressing the inactive catalytic 
ADAR1 still led to formation of dsRNA detected by slot blot (Figure 19, lane 5). Taken 
together VACV expressing ADAR1 protein in E3L locus can lead to a significant 
decrease in dsRNA and this reduction is correlated with the ability to deaminate dsRNA. 
 Expression of ADAR1 in E3L locus rescues VACVΔE3L protein expression.
 Since dsRNA made by VACV can lead activation of PKR and ultimately lead to 
protein translation shut off, we asked if expression of ADAR1 in E3L locus can rescue 
VACVΔE3L protein expression. HeLa cells were mock infected or infected with either 
VACV wt, VACVΔE3L, VACVΔE3L::ADAR1 or VACVΔE3L::ADAR1m. Cell lysates 
were prepared at 6 hours post infection. The proteins were resolved on a 10% SDS PAGE 
gel followed by western blotting using specified antibodies. We looked at 
phosphorylation of eIF2α as an indication of protein translation shut off. VACV wt has 
E3 that can sequester dsRNA thus it inhibited eIF2α phosphorylation and allowed for 
viral protein expression (Figure 20, lane 2). VACVΔE3L led to phosphorylation of 
eIF2α, thus viral protein expression was inhibited (Figure 20, lane 3). Expression of IFN-
induced ADAR1 in E3L locus inhibited eIF2α phosphorylation and allowed viral protein 
synthesis (Figure 20, lane 4). However, this rescue can only happen when ADAR1 retains 
its deaminase activity since VACVΔE3L::ADAR1m infection leads to eIF2α 
phosphorylation and inhibition of viral protein synthesis (Figure 20, lane 5). Thus, 
VACV expressing IFN-induced ADAR1 protein in E3L locus can rescue VACVΔE3L 
protein expression and this reduction is correlated with the ability to deaminate dsRNA. 
 Expression of ADAR1 in E3L locus rescues VACVΔE3L replication in HeLa.
 Since IFN-induced ADAR1 could rescue viral protein synthesis in VACVΔE3L, 
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we asked if it could lead to rescue of replication in a VACVΔE3L-restricted cell line such 
as HeLa. In order to study the replication of recombinant VACV, HeLa cells were 
infected at MOI of 1 with either VACV wt, VACVΔE3L, VACVΔE3L::ADAR1, or 
VACVΔE3L::ADAR1m. Cells were washed 3 times with warm PBS and harvested at 30 
minutes post infection (0 hour post infection) and 24 hours post infection. VACV wt 
showed approximately a 100-fold-increase in replication 24 hours post infection while 
VACVΔE3L did not show an increase in replication (Figure 21). VACVΔE3L::ADAR1 
showed approximately a 10-fold-increase in replication after 24 hours while 
VACVΔE3L::ADAR1m showed no changes in replication within 24 hours post infection 
(Figure 21). 
To ask if ADAR1 can rescue VACVΔE3L replication in a multi-step condition, 
HeLa cells were infected at MOI of 0.01 with VACV wt, VACVΔE3L, 
VACVΔE3L::ADAR1, or VACVΔE3L::ADAR1m. Cells were washed 3 times with 
warm PBS and harvested at 30 minutes post infection (0 hour post infection) and 72 
hours post infection. VACV wt showed approximately an 800-fold-increase in replication 
72 hours post infection while VACVΔE3L did not show an increase in replication (Figure 
22). VACVΔE3L::ADAR1 showed approximately a 400-fold-increase in replication after 
72 hours while VACVΔE3L::ADAR1m showed no change in replication within 24 hours 
post infection (Figure 22). Taken together, this data demonstrate the ability of ADAR1 to 
partially rescue replication of VACVΔE3L in HeLa cells, and this requires the catalytic 
deaminase activity of ADAR1. 
 Expression of ADAR1 in E3L locus rescues restricted host range phenotype 
of VACVΔE3L. VACV host range is dependent on the presence of a functional 
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E3L dsRNA-binding domain. To ask if IFN-induced ADAR1 can rescue VACVΔE3L 
host range phenotype, VACV wt, VACVΔE3L, VACVΔE3L::ADAR1 and 
VACVΔE3L::ADAR1m were titered in the permissive cell line RK13, or non-permissive 
cell line HeLa, BSC40 (African green monkey kidney cell) and JC (murine mammary 
carcinoma cell). VACV wt formed plaques virtually in all cell types even though small 
plaque phenotypes were observed in both HeLa and JC (Figure 23). VACVΔE3L did not 
plaque in non-permissive cell line (Figure 23). VACVΔE3L::ADAR1 formed plaques in 
all cell types but the plaque morphology is even smaller than VACV wt in JC (Figure 
23). And the ability to rescue VACVΔE3L restricted host range requires the ability to 
deaminate dsRNA because VACVΔE3L::ADAR1m did not form plaques in non-
permissive cell lines (Figure 23). 
 Expression of ADAR1 in E3L locus cannot restore the IFN resistance 
phenotype of VACVΔE3L. Since ADAR1 can restore the broad host range phenotype 
of VACVΔE3L, we asked if it can also restore the IFN resistance phenotype of 
VACVΔE3L. To determine this, the plaque reduction assays were performed. RK13 cells 
were treated with varying doses of recombinant IFNα/β 18 hours post infection. Treated 
cells were then infected with approximately 100 plaque-forming-units of VACV wt, 
VACVΔE3L, VACVΔE3L::ADAR1 or VACVΔE3L::ADAR1m. Cells were stained with 
crystal violet by 48 hours post infections. As expected, VACV wt is resistant to the 
antiviral effect of IFN but VACVΔE3L failed to inhibit this effect (Figure 24). 
Unexpectedly, both VACVΔE3L::ADAR1 and VACVΔE3L::ADAR1m viruses followed 
a similar trend as the VACVΔE3L infection of IFN sensitivity (Figure 24). As a result, 
the expression of ADAR1 could not rescue VACVΔE3L IFN sensitivity. 
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DISCUSSION 
 In this study, we initially set out to investigate the phenomenon of inhibition of 
delayed-late time eIF2α phosphorylation during VACVΔ83N infection in IFN primed 
cells. Our results agreed with those previously reported (99) that eIF2α phosphorylation 
was inhibited during VACVΔ83N infection in IFN primed cells. There was also a 
significant decrease in eIF2α phosphorylation during VACVΔE3L infection in IFN 
primed cells (Figure 13). This was surprising to us since IFN would increase expression 
of PKR which would lead to more activation of eIF2α. We thus hypothesized that this 
inhibition of eIF2α phosphorylation is correlated with the level of dsRNA present in the 
infected cells. 
To test the above hypothesis, we utilized slot blot and immunofluorescence 
methods. Our IF data showed that there was a decrease in dsRNA detected in both 
VACVΔE3L and VACVΔ83N infection when the cells were treated with IFN. Our slot 
blot data showed that in VACVΔE3L infection, there was a significant decrease in the 
amount of dsRNA when the cells were treated with IFN while there was a modest 
decrease in dsRNA in IFN-treated cells infected with VACVΔ83N (Figure 15). Taken 
together, the hypothesis is correct since there was a decrease in the level of dsRNA when 
the cells were treated with IFNs in both VACVΔ83N and VACVΔE3L. Previously 
published research led us to an IFN-induced enzyme that portrays a deaminase activity 
that has been shown to destabilize dsRNA structure (138). 
 Due to its close homology to E3 (Figure 16), The IFN-induced form of ADAR1 
was put into the E3L locus of VACVΔE3L in order to study its function during VACV 
infection and its ability to rescue VACVΔE3L. In addition to binding Z-NA and dsRNA, 
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the ADAR1 proteins differs from E3 in that it has deaminase activity that allows it to 
deaminate adenosines to inosines in dsRNA (13, 148). To study if this deaminase activity 
is necessary for rescuing VACVΔE3L, a catalytically inactive mutant of ADAR1 was 
also put into the E3L locus of VACVΔE3L. Our data suggests that binding to dsRNA 
alone is not sufficient to allow rescuing of VACVΔE3L but rather a synergistic affect 
between binding to dsRNA and the deaminase activity can partially recue replication of 
VACVΔE3L. 
 Our results indicate that IFN-induced ADAR1 exhibited deaminase activity in 
VACVΔE3L infection since VACVΔE3L expressing IFN-induced ADAR1 showed a 
significant decrease in dsRNA (Figure 18 and 19). And the ability to reduce the level of 
dsRNA requires the catalytic domain of ADAR1 since VACVΔE3L expressing the 
catalytically inactive mutant of ADAR1 showed no reduction in dsRNA (Figure 18 and 
19). Rescue experiments in HeLa cells demonstrate that the IFN-induced ADAR1 protein 
could rescue protein synthesis of VACVΔE3L and this ability also requires the catalytic 
domain of ADAR1 since VACVΔE3L::ADAR1m could not rescue protein synthesis of 
VACVΔE3L (Figure 20). This rescue of protein synthesis is also consistent with the 
ability of ADAR1 to inhibit the phosphorylation of eIF2α in VACVΔE3L infection 
(Figure 20). Thus, this data suggests that our phenomenon of inhibition of eIF2α 
phosphorylation during VACVΔ83N and VACVΔE3L in IFN treated cells is due to the 
activity of the IFN-induced ADAR1. 
 ADAR1 also has the ability to rescue replication of VACVΔE3L in HeLa cells. 
Our data shows that ADAR1 can only partially rescue VACVΔE3L. The partial rescue of 
VACVΔE3L by ADAR1 in HeLa cells correlates with the intermediate levels of 
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replication of VACVΔE3L::ADAR1 in both single-step (Figure 21) and multi-step 
(Figure 22) growth assay. And this ability of ADAR1 to rescue replication of 
VACVΔE3L requires its deaminase activity since VACVΔE3L::ADAR1m could not 
replicate at all in HeLa cells as well as VACVΔE3L. We further investigated if ADAR1 
can rescue VACVΔE3L in other cell lines. Our results showed that ADAR1 can rescue 
VACVΔE3L in all tested non-permissive cell lines (Figure 23) and this ability does 
require the deaminase activity. Taken together, ADAR1 can partially rescue 
VACVΔE3L’ protein synthesis and replication in non-permissive cell lines; however, this 
rescue does require the deaminase activity of ADAR1. 
 Although ADAR1 can partially rescue the replication of VACVΔE3L in non-
permissive cell lines, the IFN resistance assays conducted with the recombinant ADAR1 
virus in RK13 cell gave different results. To our surprise, both VACVΔE3L::ADAR1 
andVACVΔE3L::ADAR1m showed an IFN sensitivity trend similar to one in 
VACVΔE3L (Figure 24). This may be due to the differences in affinity between E3 and 
ADAR1 for the viral activators of the IFN response in RK13 cells. This is consistent with 
the demonstrated differences in specificity between PKR and ADAR1 dsRNA binding 
domain (150). 
 We have attempted to show deaminase activity in VACVΔE3L::ADAR1’s RNA 
transcript. However, our attempt has not been successful. Previously published data 
indicated that the Tudor staphylococcus nuclease (Tudor-SN) domain of the RISC 
complex can bind to hyper-edited dsRNA and promotes its cleavage (34). The cleavage 
sequence for Tudor-SN has been shown to be IIUI stretch base pair. This sequence has a 
normal DNA sequence of AATA which presents multiple time in VACV genome since 
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poxvirus is an AT rich virus. Since ADAR1 can exhibit hyper-editing activity, we 
hypothesized that our deaminated RNA transcript had been cleaved by Tudor-SN 
resulting in our inability to retrieve deaminated RNA sequence. In order to test this 
hypothesis, we are currently attempting to knock down the Tudor-SN protein or 
overexpressing a dsRNA that does not have IIUI base pair in VACVΔE3L::ADAR1 
infection. 
 In conclusion, here we showed that the IFN-induced gene, ADAR1, can rescue 
VACVΔE3L while provided in trans by deaminating dsRNA made by VACVΔE3L. We 
also thought that the IFN-induced form of ADAR1 is responsible for deaminating dsRNA 
made by VACVΔ83N and VACVΔE3L. VACVΔ83N still possess a dsRNA binding 
domain of E3 thus it can inhibit eIF2α phosphorylation at 6 hours post infection. 
However, we thought the amino-terminal of E3 is required to stabilize the sequestering of 
dsRNA made by VACVΔ83N; thus, VACVΔ83N failed to inhibit eIF2α phosphorylation 
at 9 hours post infection. When the cells were treated with IFNs to mount the antiviral 
state, we thought that at 9 hours post infection, dsRNA made by VACVΔ83N were 
exposed and bound to the IFN-induced ADAR1 and subsequently got deaminated by 
ADAR1 and hypothetically degraded by Tudor-SN. We also tried to transiently knock 
down ADAR1 during VACV wt and VACVΔ83N infection. Our knock down data 
showed that ADAR1 is necessary for VACV E3 protein synthesis when the cells were 
treated with IFNs. This might be due to over activation of PKR in primed cells when 
induced PKR binds to dsRNA (Supplementary figure 1). This suggests that ADAR1 is 
dampening the effect of PKR during the antiviral state and VACV possibly uses ADAR1 
to its advantage to overcome the antiviral state. Thus, ADAR1 might play a pro-viral role 
68 
 
during VACV infection. The role of ADAR1 has been studied and described in several 
RNA virus systems, this is the first time that ADAR1 is shown to have a proviral effect in 
VACV, a DNA virus.
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Figure 14 – Pretreatment of IFN reduced level of dsRNA in VACV infection. HeLa 
cells were mock treated or treated with 1000 U/ml of IFN. After 18 hours post treatment, 
cells were mock infected or infected with either VACV wt, VACVΔ83N or VACVΔE3L. 
Cells were fixed with ice cold methanol after 9 hours post infection. Cells were incubated 
with antibodies against total VACV proteins (VACV) and dsRNA. Cells were subjected 
to immunofluorescence. 
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Figure 17 – Virus construction and protein expression of ADAR1.  
A. Schematic representation of virus constructs. VACV wt represents wild type VACV, 
which encodes a full length E3 protein with a Z-NA binding domain in the amino 
terminus and a dsRNA binding domain in the carboxy terminus. VACVΔE3L represents 
virus deleted of the E3L gene, which expresses LazZ from the E3L locus. 
VACVΔE3L::ADAR1 represents VACV expressing the wild type IFN-induced 
ADAR1. VACVΔE3L::ADAR1m represents VACV expressing the catalytically 
inactive mutant of ADAR1. This mutant contains two point mutations (asterisks) 
(H910Q, E912A) in the catalytic domain that render it catalytically inactive. These 
mutations are denoted by an asterisk in the figure. B. Protein expression of ADAR. 
HeLa cells were mock infected or infected with either VACV wt, VACVΔE3L, 
recombinant VACV expressing the IFN inducible ADAR from the E3L locus 
(VACVΔE3L::ADAR) or recombinant VACV expressing the inactive catalytic ADAR from the 
E3L locus (VACVΔE3L::ADARm). . Cell lysates were prepared at 6 hours post infection. The 
proteins were resolved on a 10% SDS PAGE gel followed by western blotting using antibodies 
to ADAR1 protein. 
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Figure 19 – VACV expressing the full length ADAR1 deaminates dsRNA. 
A. Slot blot of total RNA of infected cells. HeLa cells were mock infected or 
infected with either VACV wt, VACVΔE3L, VACVΔE3L::ADAR1 or 
VACVΔE3L::ADAR1m. Total RNA were extracted at 6 hours post infection. 
100 Nano gram of total RNA were applied onto a positive membrane via 
vacuumed slots. The RNA were then UV-hybridized and blotted with antibody 
against dsRNA. B. Quantification of slot blots. Three slot blots experiments (A) 
were done. The radiography films were scanned and analyzed by TOTAL LAB 
software. 
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Figure 20 – VACV expressing the full length ADAR1 rescues 
VACVΔE3L late protein synthesis. HeLa cells were mock infected or 
infected with either VACV wt, VACVΔE3L, VACVΔE3L::ADAR1 or 
VACVΔE3L::ADAR1m. Cell lysates were prepared at 6 hours post infection. 
The proteins were resolved on a 10% SDS PAGE gel followed by western 
blotting using specified antibodies. 
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Figure 21 – Single step growth of VACV recombinant virus in HeLa. HeLa 
cells were infected at M.O.I of 1 with VACV wt, VACVΔE3L, 
VACVΔE3L::ADAR1, VACVΔE3L::ADAR1m. Cells were washed 3 times 
with warm PBS and harvested at 30 minutes post infection (0 hour post 
infection) and 24 hours post infection. Collected viruses were titered in RK13 
cells. Experiments were done in duplicate 
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Figure 22 – Multi growth of VACV recombinant virus in HeLa. 
HeLa cells were infected at M.O.I of 0.1 with VACV wt, VACVΔE3L, 
VACVΔE3L::ADAR1, VACVΔE3L::ADAR1m. Cells were washed 3 
times with warm PBS and harvested at 30 minutes post infection (0 
hour post infection) and 72 hours post infection. . Collected viruses 
were titered in RK13 cells. Experiments were done in duplicate 
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CHAPTER 3 
CHARACTERIZATIONS OF REPLICATION COMPETENT NYVAC STRAIN 
VACCINIA VIRUS AS A VACCINE VECTOR FOR HUMAN 
IMMUNODEFICIENCY VIRUS 1 
ABSTRACT 
 In 2011, there were 34 million people living with HIV/AIDS, though there is still 
no current vaccine for this pandemic.  Vaccinia virus (VACV), a member of the poxvirus 
family, was successfully used in the eradication of smallpox. Since then, it has been 
studied and developed as heterologous vaccine vector for several animal diseases. In 
2009, using ALVAC®, a member of poxvirus family, as a vaccine vector for HIV in the 
“Thai trial,” known as RV144, researchers for the first time showed that the vaccine was 
modestly effective in the reduction of HIV infection. Hence, poxvirus has been studied 
and developed for a safer and more effective HIV vaccine vector. Here we constructed 
and characterized a replication competent and immunogenic poxvirus HIV vaccine vector 
using the vaccinia virus (VACV) strain NYVAC. To achieve a replication competent 
virus, we reinserted the two host range genes, K1L and C7L, into NYVAC. The VACV 
interferon α/β receptor like protein, B19R, was removed to improve the immunogenicity 
of the vector. Our results shows that the replication competent NYVAC vaccine vectors, 
NYVAC-C-KC and NYVAC-C-KC ΔB19R, are fully replicative in human keratinocyte 
and human dermal fibroblast, express high level of HIV antigens in infected cells, and 
activate the innate signal transduction pathways while being highly attenuated. These 
preliminary data indicate that these viruses have a potential as an improved vaccine 
vectors for HIV. 
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INTRODUCTION 
Since it was first reported in the 1980s, HIV/AIDS has become one of the greatest 
pandemics of our time, effecting human personally, socially and economically. As of 
2011, there are 34.0 million people living with AIDS. Thus, the need of a HIV vaccine is 
unquestionable. Using a combination of a recombinant canarypoxvirus ALVAC® and the 
protein gp120, the phase III Thai clinical trial in 2009 observed a limited protection 
against HIV-1 infection, about 31% (163). This suggests that poxvirus vector can be used 
as one of the future HIV/AIDS vaccine candidate vectors; however, further development 
is required for a safer and effective vaccine vector. 
Vaccinia virus (VACV) is a large DNA virus that can replicate entirely in the 
cytoplasm (131). It has been used as a mean of vaccination for the smallpox pathogen 
since the method was first introduced by Edward Jenner in the 1700s (164). After the 
eradication of smallpox in 1970s, VACV has been studied and developed as vaccine 
vectors for several pathogens. VACV is considered to be a good candidate for 
heterologous vaccine vector because its ease to generate recombinant VACVs to express 
heterologous genes (130, 145). Two strains of VACV have been extensively developed as 
HIV vaccine vectors, modified vaccinia virus Ankara (MVA) and New York Vaccinia 
virus (NYVAC), which have been evaluated in both non-human primate (30, 47, 129) 
and human trials (72, 159, 172). These two vectors are safe vaccine vectors due to them 
being highly attenuated (59). The fact that they cannot replicate in human cells, thus 
preventing production of viral progeny and HIV-1 antigens, makes these two vectors not 
be able to induce strong immune response by themselves. Thus our goal is to develop a 
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replication competent HIV-1 vaccine vector in order to increase the amount of HIV-1 
antigens for better immune response while maintaining the attenuation of the vector. 
 NYVAC is a derivative of the Copenhagen (COP) VACV strain. NYVAC was 
constructed by precisely deleting 18 open reading frames (ORFs) of COP’s genome 
(197). Among those 18 ORFs are 12 continuous ORFs spanning from K1L to C7L, which 
are host range genes allowing for VACV to replicate in human cell lines as well as rabbit 
kidney cell line (68, 152). Several virulent genes were also removed in NYVAC such as: 
J2R, encoding thymidine kinase gene (TK); B13R and B14R, encoding serine protease 
inhibitor; A26L, encoding A-type inclusion body gene; A56R, encoding hemagglutinin; 
and ORF14L, encoding large subunit of ribonucleotide reductase gene. Deletion of J2R 
leads to more attenuated virus (199) and this locus was used to insert the HIV-1 clade C 
antigens. In order to make replication competent NYVAC in human cell lines, both K1L 
and C7L was put back into NYVAC genomes. In addition, to improve the 
immunogenicity of the vaccine, an additional deletion of B19R was carried out. 
The B19R gene encodes an early expressed 60-65 kilo Dalton (kDa) interferon 
(IFN) α/β receptor (IFNα/β-R) like glycoprotein. It has significant homology to cellular 
IFN-α/βRs (44) and can bind to IFNα/β and inhibit the IFN antiviral action (3). This 
protein can bind to human type I IFN with high affinity (108). It can be secreted into 
solution or can be embedded on the cellular surface of infected cells (3, 203). Deletion of 
B19R leads to attenuation of VACV in both intranasally and intracranially infected mice 
despite the fact that it binds to mouse IFN with low affinity (44, 193). 
 Our findings showed that insertion of K1L and C7L restored host range of 
NYVAC and allowed NYVAC to replicate in various human cell lines including HeLa, 
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human keratinocyte and human dermal fibroblast. Replication competent NYVAC also 
led to an increased expression of HIV-1 antigens compared to the original NYVAC. This 
can provide significant improvement in the cross-presentation, thus, making the vector 
more immunogenic. In addition, insertion of K1L and C7L did not alter the attenuation of 
NYVAC in the intracranial mouse model, ensuring the safety of NYVAC vaccine vector. 
Finally, deletion of B19R in NYVAC leads to innate immune pro-inflammatory response 
signaling, particularly in the IRF3 pathway. Taken together, by restoring replication 
competence and deleting immune-modulating gene in NYVAC, we have developed a 
safer and more immunogenic VACV vaccine vector candidate for HIV. 
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MATERIALS AND METHODS 
Cells and viruses. Baby hamster kidney (BHK-21), Rabbit Kidney (RK-13) 
cells were maintained in Eagle’s MEM (Cellgro) supplemented with 5% FBS (HyClone). 
HeLa and BSC40 (African green monkey kidney cells) were maintained in Dulbecco’s 
Modified-Minimal Essential Medium (DMEM) (Cellgro) supplemented with 5% FBS. 
Human Keratinocyte (Invitrogen) were maintained in EpiLife media (Invitrogen) with 
addition of Human Keratinocyte Growth Supplement (Invitrogen). Adult skin human 
dermal fibroblast (Lonza) was maintained in FGMTM-2 Bullet kit media (Lonza). All 
cells were incubated at 37°C in the presence of 5% CO2. The VACV Copenhagen strain 
herein is referred to as wild type VACV (VACV wt).  VACVΔE3L was generated as 
previously described (38). NYVAC-C was obtained from Sanofi-Pasteur. NYVAC-C 
ΔB19R was obtained from Dr. Mariano Esteban’s lab. 
Construction of the replication competent NYVAC-C KC and NYVAC-C 
KC ΔB19R.  This work was done by Dr. Karen Kibler in our lab and was first described 
in (92). Briefly, The C7L and K1L genes were amplified from the Copenhagen genome 
using overlapping PCR with the following primers NY1 (5' 
GTTTGCATCGTGCTTTAACATCAATGG 3'), NY2 (5' 
GTCTTACTCATTGCATCGTACGGTTGGCTTATTCCATAGTAGCTTGTG  3'), NY3 
(5' CTACTATGGAATAAGCCAACCGTACGATGCAATGAGTAAGACAATAGG 3') 
and NY4 (5' GTACCTGGCAATAGGTGATAATATGAC 3').  The “KC” fragment was 
then inserted into the NYVAC or NYVAC-C genome by in vivo recombination:  150 ng 
DNA was used to transfect MRC-5 cells according to the manufacturer’s protocol 
(Lipofectamine, Invitrogen), in 35 mm dishes; cells were infected with the parental virus, 
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either NYVAC or NYVAC-C, at a multiplicity of infection (MOI) of 0.05 by adding the 
virus to the transfection mix.  After 30 minutes of incubation, 1 ml of OptiMEM with 1% 
serum was added to each dish.  Cells were scraped into the medium at 36 hours post-
infection.  Following three rounds of freeze/thaw, the IVR scrape was used to infect Vero 
cells to select for viruses competent for large plaque formation in Vero cells.  The same 
method was used to insert KC into NYVAC-C-ΔB19R. 
Virus infection.  The virus was diluted in MEM containing 2% FBS. Cell 
monolayers in a 60 mm dishes were infected with 100 μL of virus after aspirating the 
media off the dishes. Cells were incubated at 37oC, 5% CO2 for 1 hour, with rocking 
every 10 minutes. BHK-21 cells were used to amplify the recombinant viruses used in 
this study. Stocks of recombinant viruses were generated by amplification of a single 
corrected plaque in 60 mm dish of BHK-21 cells. At 100% cytopathicity, the infected 
cells were harvested by scraping and centrifuging at 1000 rpm for 10 minutes at 4oC. The 
cell pellet was resuspended in 10 mM Tris HCl pH 8.8. Three rounds of alternate freezing 
(-80oC) and thawing on ice for 30 minutes, followed by vortexing for 30 seconds (3 
times) was performed to lyse the cells and release the virus. The prep was then spun at 
1000 rpm for 10 minutes at 4oC and the virus in the supernatant was transferred into a 
fresh tube and stored at -80oC. The virus was titered in BHK and BSC40 cells. 
PCR confirming deletion of B19R. 100 μL of virus stock with a titer of 1x109 
pfu/mL was used for DNA extraction.  Virus DNA was extracted by treating the virus 
with a 100 μL of phenol equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA 
(Sigma).  The aqueous phase from the above step was re-extracted with 100 μL 
phenol:isoamylalcohol:chloroform (25:24:1) (Sigma). The aqueous phase from the above 
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step was re-extracted with 100 μL volume chloroform:isoamyl alcohol (24:1) (Sigma), 
followed by precipitation with 2.5 volumes of 95% ethanol, 1/10 volume of 7.5M 
ammonium acetate, and 10μL glycogen (Fermentas).  The DNA was washed in 70% 
ethanol, dried and resuspended in 50 μL of distilled water. 
PCR was performed using B19R flanking primers, B19RF F (5’ 
TCACGACGAAACAATGTTAC 3’) and B19RF R (5’ 
ATGTTCTCTATCGGTGAGATAC 3’).  Briefly, 100 ng of virus DNA template, 500 
μM of B19RF F,  500 μM of B19RF R, 500 μM dNTPs, 2 mM MgCl2, 1X MgCl2 buffer, 
and Platinum Taq polymerase enzyme (Invitrogen) were mixed in a 50 μL reaction 
volume.  PCR amplifications were performed with 95ºC for 5 minutes, followed by 30 
cycles of amplification (95ºC for 1 minute, 55ºC for 1 minute, 68ºC for 2 minutes).  The 
PCR product was subjected to agarose gel electrophoresis (1%, GTG grade) at 100 volts 
for 1 hour. 
Protein extraction and Western Blotting.  50% confluent HeLa cell or human 
Keratinocyte monolayers were infected with viruses at a MOI of 5. At the indicated times 
post infection, cells were scraped into 150 μL of 1X SDS (62.5 mM Tris-Cl, 10% 
glycerol, 2% SDS, 0.0005% bromphenol blue, 0.1% 2-mercaptoethanol, 1X Halt Protease 
and Phosphotase Inhibitor Cocktail (Pierce Thermo Scientific)). Lysates were transferred 
into QIAshredder columns (Qiagen), spun at 16,000xg for 2 minutes at 4oC, and stored at 
-80oC. The samples were boiled for 5 min and ran on 10% and 12% SDS-PAGE gels at 
150V. Proteins were transferred to nitrocellulose membranes at 100 volts for 60 min in 
10 mM CAPS, pH 11 with 20% methanol. The membranes were blocked with 3% milk 
(Carnation® Non-fat Dry Milk) TTBS (20 mM Tris-HCl, pH 7.8, 180 mM NaCl, 0.05% 
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Tween-20) for 1hr. The membranes were probed with primary antibodies overnight. 
Secondary goat anti-rabbit IgG conjugated to horseradish peroxidase (1:10,000, Santa 
Cruz) or anti-mose IgG conjugated to horseradish peroxidase (1:10,000, Santa Cruz) was 
added followed by chemiluminescence (Pierce Thermo Scientific). Rabbit polyclonal 
anti-gp120 antibody was from Centro Nacional de Biotecnología; polyclonal anti-gag p24 
serum was from ARP NIBSC, Centralised Facility for AIDS reagent, UK; IRF3-P 
antibody was purchased from Epitomics; PKR-P and eIF2α-P antibodies was purchased 
from Cell Signaling, and GAPDH antibody was purchased from Abcam. 
Multi step growth assay. Human Keratinocyte or Dermal Fibroblast cells in 6 
well plates were infected with MOI of 0.01 with specified viruses. IFN treatment, as 
indicated, was added at 1000 units/ml for 24 hours prior to infection. Plates were 
incubated at 4oC for 30 minutes and rocked every 10 minutes. Plates were washed thrice 
with warm media. Half of the infected cells were harvested for 0 hour time point. Plates 
were incubated at 37oC, 5%CO2 for 72 hours. Infected cells were then harvested for 72 
hour time point. Samples were frozen and thawed 3 times (frozen at -80oC for 30 
minutes, and then thawed on ice for 30 minutes, followed by 3 minutes thaw at 37oC) to 
release viruses. Ultimately, samples were spun at 1,000xg for 10 minutes at 4oC and the 
supernatants were collected. Viruses were titered using BHK cells. The experiment was 
done in triplicate. 
Pathogenicity in newborn mice. Pregnant CD1 mice were purchased from 
Charles River at 10 days gestation. The animals were housed one animal per cage. 
Intracranial infections with the indicated viruses, using a total volume of 10 μL, were 
conducted at 48 to 72 hours post-birth of the pups (at least 10 pups per virus), using a 27-
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gauge needle, as previously described (125). Animals were monitored twice daily for 14 
days for morbidity and mortality. 
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 RESULTS 
Construction of recombinant virus. HIV-1 clade C genes were inserted 
into the empty J2R locus of NYVAC by our collaborator at Sanofi-Pasteur to generate 
recombinant NYVAC expressing HIV protein, herein referred to as NYVAC-C. Clade C 
gp120 and the poly proteins gag-pol-nef were expressed by a divergent synthetic 
early/late promoter (Figure 25). This NYVAC-C was then further attenuated by deleting 
its IFNα/β-R-like-protein gene (B19R), herein referred to as NYVAC-C ΔB19R (Figure 
25). To restore replication competency of these recombinant viruses, a cassette of K1L 
and C7L genes were inserted into these viruses (Figure 25). These replication competent 
recombinant viruses herein are referred to as NYVAC-C KC and NYVAC-C KC ΔB19R. 
 To test for the loss of B19R genes, viral genomic DNAs were extracted using 
standard phenol/chloroform extraction. PCR was done with flanking primers (300 bp 
outward of B19R gene) and the products were run on a 1% Agarose gel. As expected, 
NYVAC-C and NYVAC-C-ΔB19R still had the B19R gene intact as a 1.5 kb band were 
observed in these two (Figure 26). However, NYVAC-C-ΔB19R and NYVAC0C-KC-
ΔB19R did not possess the B19R gene as the PCR only showed a 600 bp flanking arms 
product (Figure 26). 
 To test if the insertion of K1L and C7L restored the broad host range phenotype 
of NYVAC recombinant viruses, 100-200 pfu of NYVAC recombinant viruses were 
plaqued in BSC40 and RK13 cells for 48 hours and were then stained with crystal violet. 
BSC40 is a permissive cell line for NYVAC thus, all the recombinant viruses plaqued 
NYVAC-C-KC ΔB19R did not out in BSC40 (Figure 27). NYVAC-C and NYVAC-C 
does not contain their host range genes thus they couldn’t plaque out in RK13 cells 
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(Figure 27). Only NYVAC-C KC and NYVAC-C KC ΔB19R which have their host 
range gene reinserted could plaque out in Rk13 cells (Figure 27). 
 Restoring replication competence of recombinant viruses increases 
expression of HIV-1 antigens in infected cells. To test if restoring replication 
competence of NYVAC recombinant viruses would lead to increase expressing of HIV-1 
antigen, HeLa cells were infected with VACV wt, VACVΔE3L, NYVAC-C, NYVAC-C 
ΔB19R, NYVAC-C KC, or NYVAC-C KC ΔB19R. Cells lysates were prepared after 6 
hours post infections and were resolved on a 7.5% poly-acrylamide gel followed by 
western blotting using rabbit polyclonal anti-gp120 antibody and mouse polyclonal anti-
gag p24 serum.  As expected, VACV wt and VACVΔE3L do not possess any 
recombinant gene thus did not express HIV-1 proteins (Figure 28, lane 2 and 3). Since 
NYVAC-C and NYVAC-C ΔB19R cannot replicate in HeLa (data not shown), the 
expression level of HIV-1 gp120 and the poly-protein gag-pol-nef was low, especially in 
the NYVAC-C ΔB19R infection (Figure 28, lane 4 and 6). Reinsertion of K1L and C7L 
into NYVAC recombinant viruses increases expression of HIV-1 antigens because both 
NYVAC-C KC and NYVAC-C KCΔB19R expressed a high amount of gp120 and gag-
pol-nef poly-protein (Figure 28, lane 5 and 7). 
 Restoring replication competence of recombinant viruses restores virus 
replication in primary human cell lines. To test if the addition of the K1L and C7L 
genes would restore replication in primary human cell types that are physiologically 
relevant to poxvirus infection, we analyzed multi-step growth curves in human 
keratinocytes and human dermal fibroblasts since these cells are the first layer of the skin 
cells get infected with vaccinia virus during a vaccination. Primary human keratinocytes 
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and human dermal fibroblast were mock treated or treated with IFN as specified for 18 
hours before they were infected with either VACV wt, NYVAC-C, NYVAC-C KC or 
NYVAC-C KC ΔB19R. As expected, NYVAC-C did not replicate in any of the primary 
cells due to the loss of host range genes (Figure29). In both cell lines, NYVAC-C-KC 
and NYVAC-C KC ΔB19R replicated to titers comparable to that of the VACV wt (as wt 
Cop VACV in figure) (Figure 29). When the cells were pre-treated with IFN, VACV wt 
is fully resistant to treatment with IFN thus it replicated to high titer. However NYVAC-
C-KC and NYVAC-C-KC ΔB19R did not replicate to the extent of VACV wt in IFN-
treated cells, especially in dermal fibroblasts (Figure 29). Although, this indicates that 
NYVAC-C KC and NYVAC-C-KC ΔB19R are IFN sensitive, the addition of the K1L 
and C7L genes to recombinant NYVAC did restore replication competence in human 
cells. 
 Replication competence recombinant NYVAC still have a safety profile.
 To analyze the safety profile of our recombinant viruses, we utilized a newborn 
mouse model, the most sensitive mouse model available for detecting pox virus 
pathogenesis (125). Newborn mice were inoculated intracranially (IC) with different 
doses of VACV wt (Cop as in figure), VACV wt expressing HIV-1 antigen (Cop-C), 
MVA expressing HIV-1 antigen (MVA-C), NYVAC-C, NYVAC-C KC, NYVAC-C KC 
ΔB19R and the current vaccine strain of VACV, New York City Border of Health 
(NYCBH).  As expected, VACV wt was highly pathogenic in this model, with an LD50 
of about 10 pfu.  VACV expressing HIV-1 antigen from the J2R locus is further 
attenuated by about one log due to the loss of the thymidine kinase gene, and had an 
LD50 of about 100 pfu, comparable to that of the NYCBH.  MVA-C and NYVAC-C 
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were apathogenic, having LD50 of about 107 pfu. Reinsertion of K1L and C7L into 
NYVAC-C did not restore pathogenesis of NYVAC-C KC since it was attenuated by 
approximately four logs compared to NYCBH and had a LD50 of 106 pfu.  Deletion of 
B19R from NYVAC-C-KC further attenuated the virus by approximately one log, 
approaching the attenuation of MVA and NYVAC-C (Figure 30). Thus, even though 
NYVAC-C KC and NYVAC-C KC ΔB19R replication competences were restored, they 
still acquired a safety profile because they were apathogenic in the mouse model. 
 Deletion of B19R in recombinant NYVAC led to pro-inflammatory signaling 
cascade. To determine if our recombinant NYVAC can lead to immune signaling 
cascade in infected cells, HeLa and primary human keratinocyte were mock infected or 
infected at M.O.I of 5 with either VACV wt, VACVΔE3L, NYVAC-C, NYVAC-C KC, 
NYVAC-C ΔB19R, or NYVAC-C KC ΔB19R. Cell lysates were prepared at 6 hours post 
infection. Cell lysates were resolved on a 10% poly-acrylamide gel followed by Western 
blotting using specified antibodies. As expected, VACV wt inhibited all signaling 
cascade while VACVΔE3L led to signaling cascade of PKR, eiF2α and IRF3 in both 
HeLa and human keratinocyte (Figure 31). NYVAC-C led to a minimal amount of 
phosphorylation of PKR and eIF2α but not IRF3 in both cell types whereas deletion of 
B19R from NYVAC-C led to activation of IRF3 in HeLa (Figure 31A) but not in human 
Keratinocyte (Figure 31C). Reinsertion of K1L and C7L into NYVAC-C led to inhibition 
of all signaling cascade in both HeLa and Keratinocyte (figure 31) as observed in VACV 
wt infection. Even though NYVAC-C KC ΔB19R inhibited PKR and eIF2α signaling 
cascade, thus its replication competence phenotype, it still led to IRF3 signaling cascade 
in HeLa (Figure 31A). In human keratinocyte, it was observed that it was dependent on 
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the donor whether or not NYVAC-C KC ΔB19R led to IRF3 signaling cascade. Our 
results showed NYVAC-C KC ΔB19R could lead to IRF3 phosphorylation in one 
donor’s cells while it couldn’t in other donor’s cells (Figure 31B and 31C). In the donor 
2’s keratinocyte, there was a light shifted band of IRF3 in the NYVAC-C KC ΔB19R 
infection (Figure 31C). However, this band was not observed in the positive control 
VACVΔE3L but observed in the VACVwt and NYVAC-C KC, we deduced this band 
was not the band indicating the activation of IRF3. 
In an attempt to compare our replication competent vaccine vector NYVAC-C 
KC ΔB19R to the Thai trial vaccine vector ALVAC®, HeLa were mock infected or 
infected at M.O.I of 5 with either VACV wt, VACVΔE3L, NYVAC-C, NYVAC-C KC, 
NYVAC-C ΔB19R, NYVAC-C KC ΔB19R or ALVAC®. Cell lysates were prepared at 
6 hours post infection. Cell lysates were resolved on a 10% poly-acrylamide gel followed 
by Western blotting using specified antibodies. ALVAC® led to PKR and eIF2α 
phosphorylation thus it indicated that ALVAC® is not replication competent in human 
cells. In addition, ALVAC® still did not lead to IRF3 signaling cascade while NYVAC-
C KC ΔB19R can (Figure 32). This showed that NYVAC-C KC ΔB19R can be 
considered as a vaccine vector that is fully replication competent while still maintaining 
its safety profile and its immunogenicity by signaling the IRF3 pathways which has been 
shown to be a key transcription factor in the IFN pathway. 
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 DISCUSSION 
 The results of the phase III Thai clinical study with the use of ALVAC® showed 
modest success (163); it proves that poxviruses can be considered as a vaccine vector for 
HIV. Since then, MVA and NYVAC, attenuated strain of VACV, have been considered 
as promising HIV vaccine candidates due to their high safety profile (126). However, 
both MVA and NYVAC, like ALVAC®, are replication incompetent in human cells; 
thus reducing the amount of antigen able to be expressed in the cells, limiting their ability 
to induce strong immune response on their own. Therefore, to improve these vaccine 
vectors, the method of restoring replication competence in these vectors while 
maintaining their safety profile has been considered. 
In this investigation, we have constructed a new vector with replication 
competence in human cultured cells. This was done by the reinsertion of the host 
restriction genes K1L and C7L (68, 152) into the genome of NYVAC-C, a vector that 
expresses gp120- and gag-pol-nef antigens of HIV-1 from clade C. To further improve 
the immunogenicity of this vector, we also deleted the IFN-α/β-R like protein gene, 
B19R. This gene was selected for deletion due to the high affinity of its protein to bind to 
human type I IFN (6, 108), thus interfering with the immune signaling. Here, we 
evaluated the replication competence, the safety profile and the ability to elicit immune 
signaling cascade of the following vaccine vector constructs: NYVAC-C, NYVAC-C 
KC, NYVAC-C ΔB19R and NYVAC-C KC ΔB19R 
Reinsertion of the K1L and C7L genes restored viral replication in human 
cultured cells, including physiologically relevant keratinocytes and dermal fibroblasts 
(Figure 23). Furthermore, we observed that the presence of K1L and C7L in NYVAC-C 
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and NYVAC-C ΔB19R improved the level of expression of HIV-1 antigens, especially in 
the latter (Figure 28). It has been shown that the K1L gene is necessary to prevent 
activation of PKR in the infected cells (125). Therefore, restoring the host range genes in 
NYVAC-C KC and NYVAC-C KC ΔB19R led to inhibiting PKR and eIF2α activation 
while NYVAC-C and NYVAC- ΔB19R led to these signaling cascades (Figure 31). 
Activation of these cascades leads to inhibition of protein synthesis in the infected cells 
(112). Therefore, HIV antigen expression by the viral vector is enhanced by the presence 
of K1L. Thus, we have achieved our first goal of restoring replication competence of our 
vaccine vectors and increasing the amount of HIV-1 antigens in the infected cells. 
A concern exists that the replication competent vaccine vector maybe too 
pathogenic to use as a vaccine. To evaluate the safety profile of our replication 
competence vector, we utilized the intracranially inoculated newborn mouse model.  Our 
result showed that the vector NYVAC-C-KC is highly attenuated compared to the 
Copenhagen and NYCBH strains, 105 and 104 less pathogenic respectively (Figure 30). 
The deletion of B19R has been shown to decrease pathogenicity in the mouse model (44, 
193). Thus, NYVAC-C KC ΔB19R exhibited an attenuated profile as much as MVA as 
indicated in our result. Taking this into account, we have achieved our goal to develop a 
replication competence vaccine vector for HIV while still maintaining its safety profile. 
We also looked at the ability of our construct to induce the pro-inflammatory 
signaling pathway. To investigate this, we looked at the ability of our vector to induce 
IRF3 activation, a key modulator in the IFN pathway. Our results showed that even 
though possessing the host range genes K1L and C7L that can inhibit the activation of 
PKR, NYVAC-C KC ΔB19R still led to activation of IRF3 (Figure 31). IRF3 is the key 
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transcription factor required for the induction of type I IFN, which has been known as a 
key modulator of the innate and adaptive immune responses. Compared to ALVAC® 
which did not lead to activation of IRF3, our data suggests that the immunogenicity of 
NYVAC-C KC ΔB19R may have improved due to its ability to signal the IRF3 pathway 
(Figure 32). Even though there was no immunological assay performed in this work, our 
collaborator, using microarray analysis, has showed that NYVAC-C KC ΔB19R induced 
IFN gene expression and the activation of IFN induced transcription factors that 
necessary to activate the innate and adaptive immune system (158). Unpublished data 
from our collaborator showed that the replication competent vaccine vector is capable of 
inducing strong T cell response against HIV-1 antigen in non-human primate model 
while the replication deficient vaccine vector failed to induce T cell response. This 
suggests that we have successfully developed a safe, replication competent, and 
immunogenic vaccine vector for HIV-1. In conclusion, our work demonstrated that we 
have developed a replication competent vaccine vector that still maintains its safety 
profile and its immunogenicity. Our work continues in determining the ability of these 
vaccine vectors as an HIV vaccine. Phase 1 clinical trial for these vaccine vectors are 
scheduled to be undertaken in the near future in order to access the ability of these 
replication competence vaccine vectors. 
  
102 
 
 
Fi
gu
re
 2
5 
– 
Sc
he
m
at
ic
 r
ep
re
se
nt
at
io
n 
of
 c
on
st
ru
ct
io
n 
of
 N
Y
VA
C
 r
ec
om
bi
na
nt
 v
ir
us
. N
Y
VA
C
 w
as
 d
el
et
ed
 o
f 1
8 
op
en
 re
ad
in
g 
fr
am
es
 (i
n 
re
d)
. H
IV
-1
 C
la
de
 C
 a
nt
ig
en
s w
er
e 
in
se
rte
d 
in
to
 th
e 
em
pt
y 
J2
R
 lo
cu
s o
f N
Y
VA
C
 y
ie
ld
in
g 
N
Y
VA
C
-C
. T
he
 B
19
R
 g
en
e 
of
 
N
Y
VA
C
 (i
n 
pu
rp
le
) w
as
 d
el
et
ed
 in
 N
Y
VA
C
-C
 to
 g
en
er
at
e 
N
Y
VA
C
-C
 Δ
B
19
R
 B
ot
h 
K
1L
 a
nd
 C
7L
 (b
lu
e 
an
d 
re
d 
un
de
rli
ne
d)
 w
er
e 
re
in
se
rte
d 
in
to
 N
Y
VA
C
-C
 a
nd
 N
Y
VA
C
-C
 Δ
B
19
R
 to
 g
en
er
at
e 
th
e 
re
pl
ic
at
io
n 
co
m
pe
te
nc
e 
N
Y
VA
C
-C
 K
C
 a
nd
 N
Y
VA
C
-C
 K
C
 Δ
B
19
R
   
103 
 
 
  
Figure 26 – Confirmation of the loss of B19R gene. Viral genomic DNAs of 
NYVAC-C, NYVAC-C-KC, NYVAC-C-ΔB19R, NYVAC-C-KC-ΔB19R and 
the positive control VACV ΔB19R were extracted using standard 
phenol/chloroform extraction. PCR was done with flanking primers (300bp 
outward of B19R gene) and the products were run on a 1% Agarose gel. B19R 
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Figure 28 – Restoring replication competency of recombinant NYVAC 
viruses lead to increased expression of HIV-1 antigen. HeLa cells were mock 
infected or infected with either VACV wt, VACVΔE3L, NYVAC-C, NYVAC-C 
ΔB19R, NYVAC-C KC, or NYVAC-C KC ΔB19R. Cells lysates were prepared 
after 6 hours post infections and were resolved on a 7.5% poly-acrylamide gel 
followed by western blotting using rabbit polyclonal anti-gp120 antibody and 
mouse polyclonal anti-gag p24 serum. 
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Figure 29 – Multi step growth of recombinant NYVAC1. Human 
keratinocytes (A) and human dermal fibroblast (B) cells were mock treated and 
treated with 1000 U/ml of IFN for 18 hours before they were infected at M.O.I 
of 0.1 with either VACV wt, NYVAC-C, NYVAC-C KC or NYVAC-C KC 
ΔB19R. Cells were washed 3 times with warm PBS and harvested at 3 hours 
post infection) and 72 hours post infection. . Collected viruses were titered in 
BHK cells. Experiments were done in duplicate 
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Figure 30 – Pathogenesis of recombinant NYVAC1. 1 day old mice were 
inoculated intracranially with indicated doses of VACV wt (Cop), VACV wt 
expressing HIV-1 antigen (Cop-C), Modified Vaccinia virus Ankara (MVA), 
NYVAC-C, NYVAC-C KC, NYVAC-C KC ΔB19R and the current vaccine strain 
of VACV, New York City Border of Health (NYCBH). Mice were counted daily 
and observed for 14 days post infection. 
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Figure 31 – Signal transduction induced by NYVAC recombinant virus1. HeLa 
(A) and primary human Keratinocyte (B and C) were mock infected or infected at 
M.O.I of 5 with either VACV wt, VACVΔE3L, NYVAC-C, NYVAC-C KC, 
NYVAC-C ΔB19R, or NYVAC-C KC ΔB19R. Cell lysates were prepared at 6 
hours post infection. Cell lysates were resolved on a 10% poly-acrylamide gel 
followed by Western blotting using specified antibodies.  
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Figure 32 – NYVAC-C KC ΔB19R can lead to IRF3 activation but not 
ALVAC®. HeLa were mock infected or infected at M.O.I of 5 with either 
VACV wt, VACVΔE3L, NYVAC-C, NYVAC-C KC, NYVAC-C ΔB19R, 
NYVAC-C KC ΔB19R or ALVAC®. Cell lysates were prepared at 6 hours post 
infection. Cell lysates were resolved on a 10% poly-acrylamide gel followed by 
Western blotting using specified antibodies.  
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OVERALL DISCUSSION 
 Type I IFNs are the primary first line of defense against viral infection (171). The 
IFN signal transduction pathway consists of two signaling cascades: a virus-induced IFN 
productionsignal and an IFN receptor-mediated secondary signal to establish an antiviral 
state (78, 206). The virus-induced IFN productionsignaling is initiated by the detection of 
PAMPs by host pattern recognition receptors. The most common PAMP produced by 
VACV is dsRNA (45) as a consequence of convergent transcription of late genes from 
opposite strands of the genome (55). It is thought that dsRNA can lead to signal 
transduction cascade of the RIG-I/MDA-5 pathway (223) to establish the virus-induced 
IFN production signaling via activation of IRF3 (60, 179). To overcome this, VACV 
encodes the E3L gene which expresses a dsRNA binding protein that can sequester 
dsRNA (39) from cellular PRRs; thus, inhibiting the virus-induced IFN production 
signaling. Therefore, VACVΔE3L, VACV deleted of the virulent E3L gene, can lead to 
virus-induced IFN production signaling via activation of IRF3. In the first study 
presented here, we investigated the cellular components that lead to VACVΔE3L induced 
activation of IRF3. Our first aim of the study was to examine the role of protein kinase R 
in activation of IRF3. This was accomplished by using two different methods: the 
overexpression of the dominant negative form of PKR, and virus expressing the PKR 
pseudo-substrate, vIF2αh, that can degrade PKR; we showed that PKR is necessary for 
VACVΔE3L induced activation of IRF3. Our data agreed with one reported by our 
collaborator using stably-PKR-knocked-down HeLa (228). Since PKR was reported to be 
involved in MAPK kinases signaling pathway (8, 79, 195), we hypothesized that either 
the p38 kinase or SAPK/JNK kinase are involved in PKR-dependent activation of IRF3. 
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Using pharmacological small molecule inhibitor, we found that not the p38 kinase, but 
the SAPK/JNK is required for PKR-dependent activation of IRF3. Thus, PKR is 
necessary for virus-induced activation of IRF3, but it is not sufficient. During the time of 
this study, it was reported that SAPK/JNK phosphorylates IRF3 at serine173 at the N-
terminal (226). Using an immunoprecipitation assay of overexpressed V5-tagged IRF3 
and V5-tagged mutant IRF3, we found that serine 173 of IRF3 is necessary for PKR-
dependent activation of IRF3.  Taking this into consideration, we proposed a mechanism 
of VACVΔE3L induced activation of IRF3 as shown in figure 12. During VACVΔE3L 
infection, dsRNA leads to the activation of both SAPK/JNK and IKKε. Both these 
kinases are involved in the activation of IRF3. SAPK/JNK phosphorylates the N-terminal 
of IRF3 at serine 173 in order for the phosphorylation of IRF3 at the C-terminal by IKKε 
to occur. The phosphorylation of IRF3 at the C-terminal leads to the activation of this 
transcription factor. This is the first time that SAPK/JNK is shown to participate in PKR-
dependent-activation of IRF3 via phosphorylation of serine 173 in VACV infection.  
 The second cascade in the IFN signaling pathway is the up-regulation of IFN-
induced genes. This cascade is first initiated once IFNs bind to their receptors (190) on 
the same infected cells for an autocrine effect or the neighboring cells for a paracrine 
effect. This will activate the JAK/STAT pathway (190) which results in the activation of 
multiple IFN stimulated genes which are mostly antiviral genes such as PKR, RIG-I, 
MDA5, or the OAS system. In the second study, we investigated the role of the IFN-
induced gene, ADAR1, in VACV infection. This study was initiated during our initial 
characterization of VACV E3 protein. E3 protein has two domains (29) : the amino-
terminal Z-NA binding domain and the carboxyl-terminal dsRNA-binding domain. Our 
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data from the characterization study showed that VACVΔ83N, VACV which does not 
possess the amino-terminal Z-NA binding domain of E3, inhibited eIF2α phosphorylation 
at 6 hours post infection (an initial-late phase of the infection) as expected but failed to 
inhibit eIF2α phosphorylation at 9 hours post infection (a delayed-late phase) (99). 
Interestingly, when cells were treated with IFN to mount the antiviral state, VACVΔ83N 
did not lead to eIF2 phosphorylation. Our data presented here also showed the same 
phenomenon observed for VACVΔE3L infection. Since eIF2α phosphorylation is a direct 
consequence of activation of PKR by binding to dsRNA, our first aim of this study was to 
determine the amount of dsRNA within VACV infected cells when the cells were pre-
treated with IFNs. Our data showed that when the cells were treated with IFN, the 
amount of dsRNA in VACVΔE3L infection decreased while there was only a modest 
reduction of dsRNA observed in the VACVΔ83N infection. This data suggested us that 
there are other IFN-induced proteins that reduce the level of dsRNA during VACV 
infection. During our literature research, we noticed that ADAR1 is an IFN-induced 
protein that can deaminate dsRNA (138). Further investigation showed that ADAR1 
shares close homology to VACV E3 protein. Thus, in the second aim of the study, we 
asked if the IFN-induced ADAR1 can complement the loss of E3L in VACVΔE3L. Our 
data showed that expression of IFN-induced ADAR1 resulted in a significant reduction of 
dsRNA in VACVΔE3L infection. However, this reduction required the deaminase 
activity of ADAR1, suggesting that IFN-induced ADAR1 reduces the amount of dsRNA 
by deaminating it. This data suggest that ADAR1 might be responsible for the reduction 
of eIF2α phosphorylation in IFN treated cells during VACVΔE3L infection. By 
expressing ADAR1 in VACVΔE3L, we also found out that ADAR1 can partially rescue 
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VACVΔE3L replication by restoring viral protein synthesis in infected cells when 
provided in trans suggesting that ADAR1 plays a pro-viral role during VACV infection. 
 The role of ADAR1 has been described in several RNA virus systems such as 
measles virus, influenza virus, and hepatitis D virus (HDV). In Measles virus, a non-
segmented negative strand RNA virus,  hyper-editing activity of ADAR1 in the matrix 
(M) mRNA has been shown to contribute to the persistent infection of the central nervous 
system, leading to the fatal degenerative neurological disease, subacute sclerosing 
panecephalitis (SSPE) (141). Using ADAR1-knocked-down HeLa cells, it was shown 
that measles virus infection led to enhanced cytotoxicity and apoptosis correlated with 
enhanced activation of PKR and IRF3 (201). These data suggests that ADAR1 plays a 
pro-viral role in measles virus infection. In contrast, ADAR1 has an antiviral role in 
influenza virus system, a segmented negative-strand RNA virus. It was shown that in the 
IKK-knocked-down mice, the animal was hyper-susceptible to influenza infection and 
this was correlated with the lower rate of A-I editing of the viral mRNA in the knocked-
down mice compared to the control mice (200). Furthermore, the IFN-induced form of 
ADAR1 was shown to suppress the influenza virus-induced cytopathic effects (209). 
These data suggest that ADAR1 plays an antiviral role in influenza infection. ADAR1 
also was shown to be both antiviral and proviral at the same time in virus system such as 
HDV. It was shown that the site-selective editing of viral RNA by the constitutive form 
of ADAR1 (82) is critical for genome packaging of viral particles, suggesting the proviral 
of ADAR1 in HDV (34) , a subviral satellite of hepatitis B virus. However, enhanced 
levels of editing by ADAR1, especially the p150 form upon IFN treatment, can result in 
an antiviral response in HDV (82). The role of ADAR1 in DNA virus has not been 
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characterized well. Using mouse polyoma virus (PyV), a member of the Polyomaviridae, 
it was shown that there was extensive A-I editing in early mRNA during late times after 
infection (95) but the role of ADAR1 in this system has yet been to be identified. Using 
recombinant virus expressing the IFN-inducible form of ADAR1, we showed here that 
ADAR1 could result in the reduction of dsRNA in the infected cells; hence rescuing the 
viral protein synthesis, and subsequently viral replication. Due to difficulties in obtaining 
the deaminated sequence, the A-I editing activity of ADAR1 in VACV was not shown 
here. However, our data strongly suggests that the IFN-inducible form of ADAR1 does 
play a pro-viral role in VACV infection. And this is the first time we show that ADAR1 
has a proviral role in DNA virus. 
 In chapter 1 of this dissertation, we showed that PKR, an IFN-inducible protein, is 
necessary for the activation of IRF3 in VACVΔE3L infection. On the other hand, in 
chapter 2 of this dissertation, we showed that the full length form of ADAR1, an IFN-
inducible protein, can rescue VACVΔE3L viral protein synthesis and replication. Taken 
together, we proposed a hypothesized mechanism of how these pathways interact during 
VACVΔE3L infection (Figure 33). During its life cycle, VACVΔE3L makes dsRNA that 
can lead to the activation of PKR and RIG-I/MDA5. Activation of PKR can lead to 
inhibition of protein synthesis via the phosphorylation of eIF2α. Activated PKR can also 
induce the activation of SAPK/JNK which leads to the phosphorylation of IRF3 in the N-
terminal at serine173. This phosphorylation is required for the phosphorylation of IRF3 at 
the C-terminal by IKKε which is activated by RIG-I/MDA5. This will lead to the 
production of type I IFN in the infected cells. Thus, PKR is an antiviral gene in VACV 
infection. On the other hand, IFN can lead to the induction of the full length ADAR1. 
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ADAR1 can decrease the amount of dsRNA made by VACVΔE3L. This will lead to the 
inhibition of eIF2α phosphorylation which results in the rescue of viral protein synthesis 
and viral replication. Thus, ADAR1 is a pro-viral gene in VACV infection.  
Our main goal in our lab is to develop VACV as a safer vaccine for smallpox and 
also a safer and more immunogenic for heterologous vaccine vector for other diseases 
such as HIV. The first two studies gave us some insights about how the host cellular 
antiviral mechanism works during VACV infection and how VACV evades these 
pathways. These two studies also provided increased understanding in virus-host 
interaction that we utilized during the vaccine development. VACVΔE3L can be greatly 
immunogenic due to its ability to signal the type I IFN virus-induced cascade. However, 
it does not replicate well at all in human cell lines due to its protein synthesis being shut 
down early on during the infection; thus, limiting the amount of antigen presenting to the 
immune system. Therefore, VACVΔE3L would be a safe vaccine vector but would not be 
an efficient vaccine vector. Even though, VACVΔE3L::ADAR1 can partially rescue 
VACVΔE3L, it cannot be considered as a vaccine candidate because ADAR1 possesses 
the deaminase activity that alters the coding of cellular mRNA, resulting in alteration of 
cellular protein translation. Thus, in collaboration with the Pox-T cells-Discovery-
Consortium group, we developed alternative methods to genetically modify VACV to 
become a safer and immunogenic vaccine vector. Two strains of VACV have been shown 
to be a safer vaccine vector: NYVAC and MVA. Even though they have a safe profile 
due to their being highly attenuated (59), both NYVAC and MVA cannot replicate in 
human cells, thus preventing production of viral progeny and viral antigens, making these 
two vectors not immunogenic by themselves. Thus, in the last study, we showed that we 
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have developed a replication competent NYVAC vaccine vector that expresses the HIV-1 
antigens as a safe and immunogenic VACV vaccine vector for HIV-1. Our results 
showed that by reinserting the host ranges genes: K1L and C7L, NYVAC expressing the 
HIV-1 antigens could highly express HIV-1 antigens and could replicate in human cell 
lines while still maintaining its attenuation. We also removed the B19R gene of NYVAC 
in order for our replication competent NYVAC vaccine vector being able to induce pro-
inflammatory signaling cascade. Our data showed that deletion of B19R resulted in 
activation of IRF3, a key transcription factor for the induction of type 1 IFN. This data 
suggested that replication competent NYVAC in conjunction with the deletion of B19R 
(NYVAC-C KC ΔB19R) can be immunogenic due to its ability to activate the 
inflammatory response. This activation of IRF3 is not PKR-dependent since the 
activation of PKR is inhibited in the NYVAC-C KC ΔB19R infection, which still 
possesses an intact E3L gene. Unpublished data from our lab indicated that when cells 
were treated with IFN, VACV infection could lead to activation of IRF3 without 
activation of PKR. This lead us to a hypothesis in which the loss of B19R leads to virus-
induced IFN production which can prime the cells in an antiviral state, thus allowing 
activation of IRF3 without activation of PKR in NYVAC-C KC ΔB19R infection. This 
hypothesis has yet to be proven.  
Our collaborator also found that both of the constructs: NYVAC-C KC and 
NYVAC-C KC ΔB19R led to increase in antigen cross-presentation and various pro-
inflammatory responses. Unpublished data from our collaborator’s non-human primate 
study using the replication competent virus in the same vacciniation regime as in the Thai 
trial suggested that the replication competent virus could induce a broader breath of T-
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cell response and an increased number in T-cell responses. Taken together, we think that 
our replication competent vaccine vector can perform better that the replication deficient 
vector that was used in the Thai trial due to its being safe, being able to express high 
amount of antigens, being able to establish pro-inflammatory response, and being able to 
induce strong T-cell response. With this, our replication competent based vaccine vector 
has been more developed and characterized and will be participating in a phase I clinical 
study in the third quarter of 2014. 
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1 These data has been published in the manuscript “Improved NYVAC-based 
vaccine vectors” by our lab in PloS one in 2011. Research in Chapter 3 was conducted as 
part of the Poxvirus T Cell Vaccine Discovery Consortium (PTVDC) under the 
Collaboration for AIDS Vaccine Discovery with support from the Bill & Melinda Gates 
Foundation. Research was done as a group in our lab with contribution of: Dr. Karen 
Kibler, Dr. Karen Denzler, Dr. William Arndt, Dr. Susan Holechek, Shuk-mei Wong, and 
Nobuko Fukushima.  
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Figure S1 – Knock down of ADAR1 leads to inhibit of E3 synthesis in IFN 
treated cells. Hela cells were mock transfected or transfected with either 
scramble siRNA or siRNA against ADAR. After 30 hours post transfection, cells 
were mock treated or treated with 1000U/ml of IFN. Cells were mock infected 
or infected with VACV wt after 18 hours of treatment. . Cell lysates were 
prepared at 9 hours post infection. Cell lysates were resolved on a 10% poly-
acrylamide gel followed by Western blotting using specified antibodies  
